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Primary brain tumor affects some 18,000 adults in the United States each year
(Silverberg et al., 1990; Merchant et al., 1997) and over 30% are high-grade anaplastic
astrocytoma or glioblastoma multiforme (GBM) (parney et al., 1997). According to
Kruse et al., 1989, the treatment of patients with recurrent or persistent high-grade
gliomas represents a major therapeutic challenge. The use of conventional therapy
consisting of surgery, followed by radiation therapy and chemotherapy for gliomas, has
been relatively ineffective (Jaecle et al., 1994) despite the fact that these therapies are
cytoreductive in nature (Black, 1991). Most malignancies will recur locally but may also

XlV

reappear at a different site within the brain.

A brain

tumor, once established, usually

continues to outstrip the inhibitory action of any immuno biological defense mechanisms
against it. Thus, malignant intracranial (IC) brain tumors represent a lethal neoplastic
disease in which treatment has failed to extend the lifespan of affiicted individuals, with a

GBM

having a median survival rate of less than one year (Harsh et af., 1987).This has

prompted a search for other potentially useful methods to better understand the biology of
brain tumors as well as better ways to treat them The studies outlined herein, addressed
the mechanisms behind the protection against tumor development provided by the
various cells of the innate and cellular immune response in a rat brain tumor model.
Investigations consisted of: 1) primary (1°) vaccination involving a phenotypic
examination and functional analysis of the cells of the innate immune response and the
cells of the adaptive immune response infiltrating an RT-2 glioma and the expression of
the CD25 receptor; 2) 1° and secondary (2°) vaccination that involved a follow-up on
survival as well as the phenotyping of cells of the leukocytic immune response; 3)
rechallenge of long-lived rats, from Experiment 2, in the contralateral (left) hemisphere;
and

4) acquisition of memory T lymphocytes

from vaccinated rats and the use of

lymphocyte depletion studies to determine which cells were necessary to provide a
protective vaccination against development of tumor. Thus, this study illustrated a
potential therapeutic strategy to develop treatments for

GBM patients as well

providing protection against development of tumor by the use of vaccines.

as

Gene ral Int roduction

ME CHANISMS UNDER LYING PROTECTIO N AGA INST
RT-2 GLIOMA GENE SIS IN RAT

BRAIN UTILIZING

PRIMARY AND SECONDARY VACCINATION

Glioma: The C lass ical Pe riod
According to

Burns

(1800); gliomas with their macroscopical resemblance to

normal brain tissue were known long before Virchow (Scherer, 1940). The English
referred to gliomas as "medullary sarcoma", as "encephaloide" by the French, and as
"fungus medullare" by German authors (Scherer, 1940). This period was considered one
of macroscopical research. Virchow (1863/1865) created the name "glioma" and opened
the period of combined macroscopic and microscopic study of these n eoplasms (Scherer,
1940). Not only did he distinguish two main groups of brain tumors, glioma and sarcoma,
he characterized gliomas as follows:

1) "gliomas are often enormous tumors of brain-like

appearance with slow clinical evolution";

2)

" never showing a clear limitation towards

the normal brain tissue, but resembling more a hypertrophy of the involved parts than real
neoplasms"; 3) "microscopically they are formed by a proliferation of glia cells and
sometimes of glia fibers - in the latter, the tumor is hard and in the former soft" (Scherer,
1940). These tumors correspond to what is now called "glioblastoma". Scherer, 1940
showed that clinical and pathological differences between the two main groups of brain

1

2

tumors - which dominate all modem glioma classification - had been perfectly
characterized in 1865. For the next fifty years, Virchow's work determined the methods
of glioma research. It was Strobe's (1895) work that provided the first really detailed
microscopical description of gliomas. According to Scherer (1940), Virchow had
described the essential differences of macroscopic behavior and mode of growth between
"glioma" and "sarcoma". He points out that not only was Strobe able to confirm these
differences, he was also the first to use new "specific" methods for the staining of the
histological structures. According to Scherer, (1940), Strobe's description in all essential
points were confirmed by Hennberg in 1897 and Storch in 1899.
High-grade oligodendrogliollUi, anaplastic astrocytoma and glioblastoma
multiforme (GBM) affect approximately 18,000 Americans each year with 30% of these
tumors being GBM, the most common primary central nervous system (CNS) tumor
(parney

et a!., 1997). GBM is a rapidly progressive high-grade tumor of the supportive

tissues of the brain. The use of conventional therapy consisting primarily of surgery,
followed by radiation therapy, and chemotherapy for gliomas has been relatively
ineffective (Kruse, 1994 and Merchant, 1997).

A therapeutic strategy

that would induce

an immune response that targets tumor cells specifically may ultimately be a means of
achieving their complete elimination. One of the most striking features of malignant
glioma is the state of cellular immunosuppression observed in most patients studied over
a period of twenty years (Roszman et al.,1991).Weliar and Fontana (1995) attributed

the

3

immunodeficient state of glioma patients to several different factors: 1) immune paralysis
resulting from the release of immunosuppressive factors secreted by the glioma cells; 2)
treatment of glioma patients with immune compromising drugs like steroids and
hydantoins; 3) the lack of specific tumor antigens; 4) the failure of glioma cells to present
antigen; and 5) a lack of professional antigen presenting cells (APes) in the brain.
The reported incidence of brain tumor is on the rise, although, early detection by
Magnetic Resonance Imaging (MRI) and other advanced clinical diagnostic procedures
may account for the apparent increase. Imaging technologies now make it possible to
detect very small tumors before they cause clinical symptoms. Worldwide, the incidence
of all forms of primary brain tumors ranges from 4.2 to 12.8 per 100,000 (Brewis
1966

and

et

at.,

Liebowitz and Atler,1969). Baily (1948) and Zulch and Borck (1965) reported

that medulloblastoma, cellular astrocytoma, ependymoma, pineal region tumor, teratoma
and craniopharyngioma all showed peak incidence in childhood and young adults (less
than 20 years of age). Tumors of older adults frequently involve the cerebral hemispheres

and include astrocytoma, oligodendroglioma, meningioma, pituitary adenoma, neurinoma
of the cerebellopontine angle and astrocytoma of the cerebellum, with GBM and
metastatic tumors most commonly found in people between 50 and 60 years of age
(Bruner, 1994).
Malignant gliomas have been abJe to evade aggressive conventional forms of
therapy; such as, surgery, radiation and chemotherapy, despite the increase in the

4

understanding of the biology of tumors. Most surgically removed malignancies will recur
locally, but about 5% of the time they will recur at a different site within the

brain. A

tumor, once established, usually continues to outstrip the inhibitory action of any
immuno-biological defense mechanisms against it.
Reasons for this weak response by the host are:

1) the central immune system of

those who develop tumor may be impaired so that an effective immune response can not
be mounted against the tumor;

2)

changes in the surface p roteins of

the tumor cells may

block the immune response with peripheral sensitization of lymphocytes;

3)

secretion of

immunosuppressive factors, such as transforming growth factor-f) (TGF-f)), which
decreases the ability of the host's immuno-surveillance system to recognize and attack
the tumor; 4) the striking heterogeneity that characterizes GEM., in that there is no known
tumor-specific antigen or receptor that is common (Debinski et al., 1999) and 5) extreme
dissemination of glioma cells within the brain due to passive perivascular cell placement
mediated by the cerebro-spinal fluid (CSF) and an active cell migration (Pedersen et a!.,
1995).
The significance and completion of this study was that despite the great hope of
immunotherapy, cancer cells are masters of deceit and disguise that can readily alter
themselves to evade immunologic recognition and attack. Because the race is between
immune control and escape, the best strategies to combat cancer will need to attack it on
several fronts. Opportunities that have been explored include constructing vaccines that

5

combine a variety of antigens (polyvalent vaccines); testing how well antibody and
vaccine-based approaches work together; and combining nonspecific and specific
immunotherapies and other cancer therapies. Many promising opportunities wait to be
studied. Perhaps these therapies will yield cures - the universal objective of cancer
researchers. Developing therapies that can change the nature of cancer from a progressive
disease to one that may be controlled throughout life may be a more achievable and
realistic aim.

A d aptive Versus Innate Immune Respo nse

The immune system has evolved into two parts: one that is responsible for an
immediately responding, non-specific response called the "innate immune response" and
one that depends specifically on the immune challenge and requires plasticity and
memory called the "adaptive or acquired immune system" (Becher et ai., 2000).
Leukocytes are responsible for both adaptive and innate immunity. In 1997, Medzhitov

and Janeway made it clear that these two systems are not separate, but are functionally
intertwined and the actions of one has a profound effect on the other.
The innate immune system allows recognition of foreign material or matter via
germ-line encoded pattern recognition via specific antigen-receptors generated by
somatic recombination. Adaptive immune responses depend upon lymphocytes. B and T
lymphocytes are the cellular members of the adaptive immune system. These are
generated in primary lymphoid tissues- bone

ow and thymus. They populate the

marr

6

secondary lymphoid structures- lymph nodes and spleen. These lymphocytes provide life
long immunity that can follow exposure to disease or vaccination.
Granulocytes are the first cells that migrate into tissues in response to invading
pathogens. Granulocytes are a diverse collection of cells that include eosinophils, mast
celis, basophils and polymOIphonuclear (PMN) leukocytes- neutrophils. Their principal
role in inflammatory and immune responses has long been thought to be the phagocytosis
and killing of bacteria, via the generation of reactive oxygen intermediates and the release
o f lytic enzymes stored in granules (Cassatella, 1995).These cells are referred to as
granulocytes because they contain prominent cytoplasmic granules. Non-granular cells of
the innate immune response are monocytes and macrophages. Together, the adaptive and
innate immune systems provide an effective defense system

Primary and Second ary Organs:
The cellular members of the adaptive immune system are Band T lymphocytes.
These cells are generated in bone marrow and thymus and recirculate in spleen and
lymph node. They survey other organs through the blood and lymphatic systems in search
of pathogens and/or foreign substances. Since the immune privilege of the CNS is not
complete, Wekerle et al. (1987), suggested there is a certain degree of ongoing traffic of
i mmune cells and molecules through the blood-brain barrier (BBB), and transport to
regional lymph nodes. Due to this immune surveillance, trafficking in the neuro-immune
network is initiated in the CNS.

7

Bone Marrow: Primary Lymphoid Tissue
The bone marrow is soft tissue found within the bones of the skeleton of the body
and is the site of production of new blood cells or hematopoiesis. The various cell types it
contains are adipocytes, stromal cells, and blood fonning cells (hematopoietic tissue).
The bone marrow is the location of stem cells of all blood elements, including the
precursors of lymphoid cells. T hese stem cells- multipotent hematolymphomyeloid stem
cells and their progeny - are organized into groups within fatty tissue. The various cell
lines found in the bone marrow are red blood cellslerythroblasts,
macropbages/monoblasts, platelets/megakaryocytes, polymorphonuclear
leukocytes/myeloblasts, and lymphocytes/lymphoblasts.
The bone marrow is not the site of reaction with, or response to Ag. Marro w
lymphocytes circulate from the marrow to other lymphoid organs and differentiate into
lymphocytes capable of immune function. Cells originating in the bone marrow populate
the thymus where they may differentiate into T cells, whereas Blymphocytes
differentiate in the secondary lymphoid tissue.

Thymus: Primary Lymphoid Organ
Thymic structural heterogeneity derives from its embryological origins - its
development requires significant input from all three germ layers. The epithelium is
derived from the

3rt! and/or 4th pharyngeal pouch endoderm.

Phenotypic studies have

shown that the first epithelium to develop is cortical, followed by small medullary islets

8

which expand in synchrony with the appearance of mature T celis, and subsequently the
capsule toward the end of embryogenesis or even neonatal period (Boyd

et al., 1993).

The thymus is encapsulated by a thick outer layer of connective tissue and a thin
connective tissue layer directly overlying the cortex. The subcapsular sinus separates
these layers. Fibroblasts and type

1 collagen-rich trabeculae penetrate the cortex and

terminate at the cortico-medullary junction (Boyd

et a!., 1993). These trabeculae lobulate

the thymus and provide a structural link with the inner medulla. Trabeculae contain
fibroblasts, adipocytes, eosinophils, neutrophils, plasma celis, mast celis, macrophages
and granulocytes and are well vascularized and innervated. Lining the subcapsule and
trabeculae is a basement membrane supporting a flattened epithelium. This creates a
barrier between the external and internal thymic environments. Boyd (1993) describes
the internal base of the trabeculae as having perivasculature spaces which constitute the
blood-thymus barrier.

The subcapsular/subtrabecular region is one of the most important in the thymus.
It initiates thymopoiesis and produces thymic hormones (Kendall, 1991). Determinates
specific for this region have been identified and the region labeled by Thy. 1 in humans
(Boyd, 1993).
The thymic cortex can be differentiated from the medulla because the
lymphocytes are much more closely packed in the cortex. There are no afferent
lymphatics in the thymus. The cortex is an area of active proliferation., with turnover of
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cells every 3 or 4 days (Miller, 1993). According to Boyd (1993) and Miller (1993),1%
of the lymphocytes produced leave the thymus via blood vessels; the other 99% are
destroyed locally via apoptosis.
In the cortex. many thymocytes are located within vacuolar membranes of large
epithelial cells known as thymic nurse cells. These 1ymphoepithelial cell complexes
provide a close association between intact, actively dividing thymocytes and large
cytoplasmic vacuoles of the epithelial nurse cells. It is within the thymic nurse cells,
which are epithelial reticular cells, that thymocytes may learn to identify self from
nonself. Prothymocytes arriving from the bone marrow develop receptors for major
histocompatibility complex (MHC) markers. At the time of positive selection, the
prothymocyte expresses both the CD4 and CD8 co-receptor molecules. At the end of the
selection process, mature thymocytes ready for export to the periphery express only one
of these two receptors. CD8 thymocytes have receptor for Class I MHC molecules.

T

cells that express CD8 are programmed to become cytotoxic effector cells. CD4
thymocytes have receptors that recognize peptides bound to selfMHC Class II
molecules. CD4+

T cells

are programme d to become cytokine-secreting cells. Thus,

positive selection also determines the cell-surface phenotype and functional potential of
the mature T cell, selecting the co-receptor that it requires for efficient Ag recognition
and programming it for appropriate functional differentiation upon activation of the
immune response.
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High affmity self-reactive thymocytes, that might give rise to autoimmune
disease, are removed by negative selection at the junction of the medulla after reaction
with thymic dendritic cells which are rich in MHC molecules. The surviving cells are

then ready for release into the circulation and for further maturation in the peripheral
lymphoid organs.
The medullary epithelium, represented by Hassal's corpusles, express different
phenotypes as differentiation from medullary epitheloid reticular cells to endocrine
epithelium where mature Hassal's corpuscles occur. Thymocytes also show
differentiation-related phenotypic changes from cortex to medulla as defined by
phenotypic

markers identified by monoclonal antibodies. The subcapsular cortex

contains the least mature thymocytes. In the deep cortex more differentiated thymocytes
are seen. Maturation to even more m ature thymocytes occurs in the medulla. Further
differentiation occurs after the cells leave the thymus and reach peripheral lymphoid
organs.

Lymph Nodes: Secondary Lymphoid Organs
Lymph nodes (LNs) are small organs occurring in series along the course of
lymphatic vessels. Their parenchyma consists of a highly organized accumulation of
lymphoid tissue. Cells of tbis tissue recognize antigenic materials in the lymph that
percolates through the node. This induces a specific immune response. LNs are rich in
macrophages, which clear the lymph of undesirable cells, invading microorganisms, and
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other particulate marter.
LNs are located in areas of lymphatic drainage in the body and serve as filters for
tissue fluid in lymphatic vessels. Classically, the organ is divided into the inner zone, the
medulla, surrounded by the outer zone, the cortex. In the classic concept of theLN
architecture, the LN comprises a superficial cortex containing lymphoid follicles
alternating with interfollicular regions, a deep cortex or paracortex and a medulla (van
den Cord et aI., 1 985). There are three kinds of spaces in each of these regions: 1) an
intralymphatic space; 2)

an

intravascular space; 3) and an extravascular space or

interstitium. Both the vascular endothelium and lymphatic endothelium are specialized in
different regions of the node (Fossum and Ford, 1985).
They point out that the intercalation ofLNs in the lymph stream serves a dual
purpose in the defense of the body. First, phagocytes residing within theLNs ingest
invading organisms arriving via the lymph and thus reduce the load of organisms
reaching the blood stream. Secondly, according to Gowans and Knight (1964),LNs are
ideally located as control posts for the immune system This is because lymph draining
wide areas is funnelled through their narrow confines. This allows the surveillance
function of the immune system to be concentrated in small LN volumes. This results in
patrolling lymphocytes continuously entering LNs from the blood stream by crossing the
wall of the specialized postcappillary venules (Gowans and Knight, 1 964), to leave again
within a few hours in efferent lymph if they fail to meet an Ag they recognize. Studies by
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Herman

et aI., (1972), Cahill et aZ. (1976), Hay and Hobbs (1977), and Drayson et aI. ,

(1981) found that after local antigenic stimulation, specific lymphocytes are concentrated
in the regional LNs. This is due to a combination of an enhanced rate of lymphocyte
traffic into the nodes associated with increased blood flow and selective retention of Ag
specific lymphocytes within the nodes. The recruitment of specific lymphocytes from a
large recirculating pool serves to

amplify

the immune response. The chances of a

successful encounter between Ag and specific lymphocytes are, according to Unanue

et

aZ . (1984), further increased by the strategic position of APCs in the middle of
lymphocyte traffic areas within LNs.
APCs function primarily by displaying Ag in highly immunogenic forms on their
surfaces. Ag, according to Mandel

et aI., (1984), can also be retained for prolonged

periods on the surface of follicular dendritic cells within the nodes, whereby repeated
stimulation ofB lymphocytes occurs in the absence of renewed external challenge. This
generates immunological memory in B cells over an extended period of time. In
summary , LNs are the sites of confluence of lymph-borne Ag and blood-borne
lymphocytes.

SpZeen: Secondary Lymphoid Organ
Like the LN, the human spleen is a highly compartmentalized organ. Each
compartment has its own structure, cell population, and functions. The lymphoid follicles
and the surrounding lymphoid tissue is called white pulp and the sinusoidal area, which
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usually contains large numbers of red blood cells, is called the red pulp. A zone of
densely packed lymphocytes surrounding the central arteriole contains T cells, while B
cells are found surrounding the germinal center. The mantel surrounding germinal centers
is composed mainly o f B cells, but also T cells believed to be pushed aside from the B

cell zone by formation of the germinal center. In humans, there are two main functions:
production of immunological responses against blood-borne Ags and removal of
particulate matter and aged or defective blood cells, particularly erythrocytes, from the
circulation (van Krieken and Velde, 1988).

Cells of the Amnastic Immune Response:

T Lymphocytes
T lymphocytes are not able to recognize free Ag but rather their recognition of
Ags involves an interaction o f the T cell receptor (TCR) with fragments of Ag bound to
e ither class I or class II major histocompatibility complex (MHC) molecules on the
surface of APe. Cells that are capable of processing Ags and displaying them on their
surfaces are referred to as antigen presenting cells (AP C) .

As

defined by Fabry and Hart,

( 1993), all of the events that take place between uptake of Ag and T cell recognition are
called "Ag presentation". This Ag presentation is dependent on specific and non-specific
signals. Ag-specific T cells are activated through their clonaliy restricted T cell receptor
(TCR) complex. Class I restricted T cells show almost exclusively CD8+
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cytolytic/suppressor phenotypes, whereas Class II-restricted cells are CD4+ T-helper cells
(Fabry et al., 1 993). The TCR is a disulfide-linked heterodimer made up of two chains,
either a and p chains on the aj3 T cells or y and 0 chains on the yo T cells (Allison et al.,
1 987; Raulet et aI., 1 989). The a� chains function together

as

Ag receptors on mature ap

T cells. The precisely defined TCR repertoire is formed during thymic development using
four different gene segments: the variable (V), diversity CD), joining (1), and constant (C)
regions. These gene segments come together in random fashion and are expressed as a
single protein molecule containing the a (VaJaCa) and P(Vj3DPJj3CP) chains (van
Ewijk, 1 991). Upon leaving the thymic environment, the individual mature cells have
specificity. This specificity is determined by the variable regions of the ap TCR a and p
chains which form a combining site that has contact residues for both the MHC-bound
peptide and the MHC molecule (Kappler et al., 1 987; von Boehmer et aI., 1 989 and
Fowlkes et al., 1 989).
Secondary signals are also generated as result ofthe TCR-Ag-MHC interaction
and are transmitted through CD3. CD3 is a multimolecular complex expressed in a
noncovalent association with the TCR on the surface of all mature T cells. 1be CD3
complex includes invariant chains y, �, () and C (Clevers et aI., 1 988). An example of a
secondary signal is phosphoinositide-specific phospholipase C, which mediates
breakdown of inositol phospholipids, in turn giving rise to two second messengers,
inositol phosphates and diacylglycerol. According to Fabry et al., ( 1 993) the resulting
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increase in intracellular Ca2+ concentration and translocation of protein kinase C (PKC) to
the plasma membrane are thought to initiate the cascade of biochemical events leading to
activation ofT cell effector functions and clonal expansion. The consequences ofT cell
activation are the presentation of Ag and stimulation of the T cells. This results in
lymphokine gene transcription, translation, and secretion. This in turn influences
activation, proliferation, and differentiation ofT cells, B cells, and a variety of other cell
types in the microenvironment of the T cell response.
Several different APCs play a major role in T-cell activation. These include
mononuclear phagocytes (monocytes, macrophages), B lymphocytes, and Langerhansdendritic cells. These cells are referred to as "professional" APC. They generally express
MHC Class II molecules constitutively, which can be further up-regulated with
cytokines. They can also express several co stimulatory molecules such as IFN-)' and
Class II on B cells, and increased Class II on macrophages and dendritic cells.

T

LymphoCYtes of Both the Naive

and

the Memory Phenotype:

A fundamental feature of vertebrate immune systems is immunological memory
(Mackay, 1 99 1 ). The term "immunological memory" is used to describe the rapid and
enhanced immune responses to specific pathogens that have been previously
encountered. Memory is thought to be a feature among long-lived cells and this can be
years later and produce a faster and larger response. These cells are also present at higher
frequencies compared to their nalve precursors through clonal expansion (Mackay, 1 99 1 ) .
A systemic immune protection is provided by these cells as they are distributed and
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recirculate through the body. Mackay suggested that a major advance in understanding
memory has been the characterization of numerous cell surface molecules that distinguish
memory T cells from naive T cells.
T cell subsets were first identified by a CD45 monoclonal Ab (mAb) in 1 9 8 1
(Sanders e t ai., 1 98 8). Moriority, ( 1 985), Rose e t ai. ( 1 985), and Tedder e t ai. ( 1 985),
several years later independently reported functional characterization of these subsets or
their association with a particular disease (Sanders et ai., 1 988). The CDw29 mAb 4B4
marker was identified by Morimoto and coworkers, ( 1985). The CDw29 mAb 4B4
showed increased binding to the same T cell subset that had decreased CD45 expression
(Morimoto, et

aI., 1 9 8 5 , Smith et al., 1 986, Sanders et al., 1 9 8 8 ; Budd et al., 1 987).

Subsequently, additional mAbs were identified that distinguished T cell subsets sharing
functional attributes of the CD45-high and CD w29-high subsets. Two flow cytometry
was used to give a direct comparison of markers. These data showed that these differed in
expression of CD45 and CDw29, but also that of five additional surface markers
(Sanders, 1988; Me, 1 988; Makgoba, 1988 and Sharrow, et aI., 1 98 8) . These markers are
the most useful for enumerating or sorting T cell subsets.
It was thought that these subsets represented different lineages ofT cells, e.g.
CD4+ and CD8+. Tedder and coworkers, ( 1988) instead proposed that they consisted of
cells at different maturational stages. According to Saunders et ai., ( 1 988) this theory is
now supported by the resuhs from many laboratories that have shown that the peripheral
blood T cells of the CD45R- high subset convert to the CDw29-high subset, but
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conversion in the opposite direction has not been reported.. Thus, T cell expression of
many surface molecules changes with T cell activation. These investigators singled out
six aspects of functional differences between subsets: 1 ) differentiation into memory cells
is accompanied by biochemical changes which make them more sensitive to CD2 and
CD3 receptor-mediated activation and may result in enhanced responsiveness to low
concentrations of foreign Ag; 2) activation of memory cells leads to secretion of large
amounts ofIFN-y and Interleukin-3 (IL-3), while activation of naive cells results in little
or no secretion. In contrast, naive and memory cells secrete comparable amounts of IL-2
in response to

PHA stimulation; 3) memory cells differ from naive ones in their use of

accessory molecules CD4 and CD8. It is suggested that this may reflect higher affinity
specific receptors, enhanced signal transduction via CD3 or other biochemical changes
affecting the function of accessory molecules in memory cells; 4) naive cells proliferate
preferentially in response to certain immunologic stimuli such as phytohemrnaglobin
(PHA) and to autologous non-T cells. These cells are preferentially responsive to
particular conditions of CD2 and CD3-mediated stimulation, naive cells can be activated
preferentially when other signals are delivered; 5) the ability to mediate suppression is
not unique to naive cells because memory cells can also induce the suppression of Ag
specific B-cell responses; and 6) memory cells are slightly larger than naive cells. This
cell size increases with activation and after memory cells have undergone prior
activation. In summary , immunological memory' s main feature is that it is specific, long-
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term and systemic.

An

immune response in any one site will lead to a memory-type

response upon challenge in another tissue. This is achieved through the dissemination and
recirculation of memory cells throughout the body.
Westermann ( 1997) stated that in humans, approximately 5x10 1 1 lymphocytes
leave the blood each day, migrate into the tissues and return into the blood in their
continuous search for specific Ag. T cells recirculate through the body by one of two
basic pathways: 1) the vast majority recirculate by crossing high endothelial venules
(HEV), and 2) after about1 8-20 hours residency in a LN, and leave through the efferent
lymphatic duct (MacKay, 1991). T lymphocytes may also leave the blood in peripheral
vascular beds, particularly within inflammatory lesions. Local LNs receive these
draining cells via the afferent lymphatic vessels. CD4+ T cells of both the naive and the
memory phenotype enter LNs and Peyer's Patches via HEV. However, within the tissue
their migratory behavior differs. About 1 0% of these lymphocytes enter LN and Peyer's
Patches (PP) via HEV and leave via the efferent lymphatic vessel This leaves over 90%
of the lymphoeytes migrating through these organs (Fossum and Ford, 1985). Due to the
specialized environment of LN and PP, concentrated Ag is directly situated in the path of
recirculating lymphocytes. This optimizes the chance of specific T cells finding their
cognate Ag (Fossum and Ford, 1 98 5).
Mackay, ( 1 99 1), mentioned a study in which sheep were used to investigate these
two compartments of recirculating cells. The study revealed that there is a striking bias in
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the class o f T cells that take these two migration pathways. These suggested migration
pathways are : 1) T cells in peripheral afferent lymph, draining tissue such as th� skin,
were entirely of the memory type; and 2) T cells within efferent lymph; the vast majority
of which originate from the blood via

HEV,

were overwhelmingly of the naive T-cell

type. The study demonstrated that nalve T cells entered LNs by crossing HEY. Memory
T cells entered tissues and drained to a regional LN through afferent lymphatics. The
efferent lymph also was used by both naive and mT cells to leave the LNs and return to
the blood. Once they left by the efferent lymphatics, they repeated their respective
recirculation pathways.

Phagocytes in Gliomas:

Macrophages:
The monocyte-macrophage system is a network of specialized phagocytic cells
widely scattered throughout the body. These cells include peripheral blood monocytes,
dendritic cells, Kupffer cells of the liver, macrophages of LNs and spleen, fixed
macrophages of other tissues, and

CNS microglia (Lorusso and Rossi, 1 997). Available

evidence suggests that peripheral blood monocytes originate from bone marrow
precursors and that tissue macrophages, including brain macrophages, are derived from
circulating monocytes that migrate into tissues where they become resident (Kinney and
Armstrong, 1 997).
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Bone marrow precursors therefore maintain the pool of peripheral blood
monocytes and tissue macrophages. Fujita et al., ( 1 976) and Oehmichen and Huber,
( 1 976), indicated that some of the CNS macrophages derive from resident microglia. del
Rio-Hortega recognized microglia in 1 932 by means of silver carbonate impregnation
(del Rio-Hortega, 1 9 1 9 and 1 932). Microglia, originating from embryonic mesenchyme,
distribute to the CNS white and gray matter where they become resident macrophages,
and comprise between 5% and 20% of the total glial population (Lawson et a/., 1 99 1 ) .
As mentioned, monocytes originate from non-lymphoid precursors within bone
marrow and circulate in the peripheral blood with a half-life of 1 to 3 days (Haynes and

Denning, 1 993). Monocytes leave the circulation by margination into the connective
tissue. The maturation and differentiation of monocytes into macrophages is influenced
by various processes including chemotactic factors (Mauri et ai, 1 98 7 ; Verghese and
Snyderman, 1 989). Lymphocytes

(Ball.'Wi.ll,

1 989), bacterial endotoxins (Levy and Cole,

1 989), plasma proteins (Ross et al., 1 989) and cell surfaces are such examples (Berton
and Gordon, 1 983).
Macrophages bearing MHC Class II receptors and Interleukin-2 receptors (ll.-2R)
participate

in the immune process as APCs. Other immune mechanisms include antibody

dependent cell-mediated cytotoxicity (ADCC) through the binding with Fc receptors of
killer cells, and non-MHC specific restricted cytotoxicity (Tada and de Triboleta, 1 993 .)
Ag presentation by macrophages is a process involving two signals. Signal 1 is
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Ag-specific and originates from the binding of the APC receptor to the peptide-MHC
complex. S ignal 2 is Ag-nonspecific and is triggered by the B7 molecule exclusively
expressed by APCs, which interacts with CD28 expressed on Th cells. Signal 1 , in the
absence of Signal 2, results in T cell inactivation or "T cell anergy". Macrophages may

also be stimulated to release lysosomal enzymes following interaction with antigenantibody complexes (Ferreri et ai, 1 986) and with lymphokines, e.g. IFN-y, and to
operate selective targeted-phagocytosis and opsonin-mediated phagocytosis (Berry and
Butt, 1 997).

N eutrophils:
Neutrophils, also known as polymorphonuclear (PMN) cells, are terminally
differentiated, short lived cells, and incapable of proliferation. PMNs are the most
common type ofleukocyte in blood, but not in rats, and constitute 40-70% of the
circulating nucleated cells (Wheater

et al., 1 993). Histologically, the prominent features

of the PMN cells are ( 1 ) their highly lobulated nucleus; when mature, there are usually
five lobes connected by fine strands of nuclear material; (2) their high motility and
phagocytic activity; and (3) their principal function in the acute inflammatory response to
tissue injury where they ingest and destroy damaged tissue and invading microorganisms, particularly bacteria (Wheater et

al., 1 993).

The cytoplasm of neutrophils is lightly stippled with azurophilic granules which
represent large lysosomes. These are often referred to as primary granules that appear
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during neutrophil maturation. These granules contain characteristic acid hydrolases but
also a number of bacteriocidal agents including myeloperoxidase.
To be cytotoxic after antigenic activation, neutropbils require stimulation by
complement factors, leukotrienes, or other cytokines whereas lymphocytes become
cytotoxic or antibody-producing after antigenic challenge. Experimentally, there are data
that neutrophil infiltration into gliomas can occur in response to cytokines. Wright and

Merchant ( 1 997) showed a marked infiltration of leukocytes (mostly neutropbils) in the
RT -2 rat glioma model after an IC injection of tumor necrosis factor-a (TNF-a).
Fossati et al., ( 1 999), reported on the results of an analysis of infiltration of
neutropbils in human gliomas. Sections of tissue were stained for CD 1 5+ and
myeloperoxidase+ cells. Their analyses showed that over 70% of all gliomas analyzed
bad s ignificant neutrophil infiltration and there was a marked and significant correlation

between tumor grade and the extent o f the neutrophil infiltration. Of the low grade
tumors, only 40 to 50% had significant infiltration; however, in GBM over 85% of the
samples analyzed had significant infiltration. The presence of neutrophils in areas of
necrosis suggests that these infihrating cells may play an important role in glioma
pathology; i.e., they could be responding to necrotic lesions or could be promoting cell
death and destruction.
A

mounting body of evidence indicates that PMN survival can be extended

following exposure to rnicroenvironmental signals in infection and immunity. These
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signals include lipopolysaccharide (LPS),

IL- l �, TNF-a,

interleukin- 6 (IL-6), IFN-y,

granulocyte-colony stimulating factor (G-CSF), and granulocyte macrophage-colony
stimulating factor (GM-CSF) (Cassatella, 1 995). Neutrophils should be considered not
only as active and central elements of the inflammatory response, but also as cells that
through cytokine secretion, may significantly illfluence the direction and evolution of the
immune response.

G ranu locytes:

Mast Cells:
Mast cells (MCs) occur in many organs and tissues, including the CNS of several
species, including humans (Ibrahim, 1 974). MCs are highly granulated connective tissue
cells that store and produce a number of inflammatory mediators (Compton, 1 952).
Neumann, 1 890, identified them over a century ago in brain infarcts and at the edge of
multiple sclerosis. According to Hebda et at., 1 993, tissue MCs are normally distributed
widely throughout different organs such as the skin, upper and lower respiratory tract and
gastrointestinal tract. In most issues, including the skin, MCs are generally concentrated
around small blood vessels, lymphatics and nerves (Eady et aI., 1 979). Specialized
intercellular contact between mast cells and fibroblasts have also been documented. In
addition to their cytoplasmic projections, mast cells have the expected normal
comp liment of cellular organelles (Greenberg and Burnstock, 1 983). However, the most
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characteristic morphological feature of these cells is the presence of numerous
cytoplasmic granules which are individually enclosed in a bilayered membrane ( Craig et

aI., 1 988 ).
Two types of granular cells are seen and are referred to as Type I cells and Type

IT cells (Ibrahim, 1 974). Both types have been seen in the CNS of the mouse, rat, hamster
and cat while the CNS of the guinea pig, rabbit, dog, monkey and man contained almost
exclusively Type IT cells (Ibrahim, 1 974). Type I cells in the adult were generally oval or
rounded with a central oval or rounded nuclei. Ibrahim, ( 1 974), describes these cells as
containing round and uniform granules, about 0.2-0.5

urn

in d iameter which often

masked nuclear detail. By electron microscopy the cells were seen embedded in an
extension of the basement membrane system of the blood vessel and had pseudopod-like
surface extensions (Ibrahim, 1 974).
Type II cells of the rodents and the monkey, and some of those of the dog and
adult human were regular oval or spindle-shaped (Ibrahim, 1 974). By electron
microscopy, Ibrahim, 1 974, has shown that these cells had many features in common
with Type I cells, the main differences being the larger and variable granule size and the
greater homogeneity and darkness of the granules, probably reflecting their greater lipid
content.
Regarding distribution of these cells within the CNS parenchyma both types of
cells were located around arterioles and venules but not around capillaries (Hebda et aL,

1 993). No cells were normally seen at a distance from a blood vessel except in the
leptomeninges, in the nerve fiber layer of the olfactory bulbs and in the choroid fissures
and plexuses.
Type I cells are scanty in the mouse but more plentiful in the adult rat. MCs,
according to Gruber et aI., 1 995, are often found near blood vessels in the resting state
and it is widely recognized that mast cells associate with newly forming microvasculature. Thus, early accumulation of masts cells locally at a tissue site appears to
potentiate vessel growth.
Type II cells were numerically proportional to the richness of regional blood
supply. Gray matter, because of its wealth in such vessels, contained more cells than did
white matter (Ibrahim, 1 973). For the same reason the cerebral cortex contained more
cells than most other grey matter areas.
Mast cells (MC) are involved in infammatory and hypersensitivity reactions (Galli

et al., 1 984) and occur in many peripheral tissues, in perivascular regions, in close
apposition to innervating sensory or autonomic nerve fibers (Bienenstock et aI., 1 987)
and also within the peripheral nervous system and CNS (Johnson, D. and Krenger, W.,
1 992).

As

suggested by Leon et aI., 1 994, neurons and immunological mediators such as

neuropeptides or immunoglobulin E (lgE) can affect the state of mast cell activation.
According to Ratzlaff, R et al., ( 1 992) secretory products of activated MCs can stimulate
or facilitate axon reflexes, thereby inducing positive feedback loops. Activated MCs also
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secrete a wide array of pluripotent cytokines and other inflammatory mediators and
therefore, may act as bidirectional carriers of information between the nervous and
immune systems (Leon, A et aI., 1 994).
MCs are also classically associated with allergic response and are secretory cells found
primarily in connective tissue such as the lungs and skin (Dimitriadou., 1 990). These cells
synthesize and secrete numerous powerful mediators such as : endorphins, histamine,
kinins, leukotrienes, prostaglandins, serotonin, vasoactive intestinal peptide, proteolytic

enzymes and phospholipases ( Baloyannis, S. and Theoharides, T., 1992).
Bienenstock, J. et ai., ( 1 987) and others report that a close relationship exists
between the nervous system and the immune system. This could explain such
pathological conditions as inflammatory processes, asthma., vascular headaches, certain
tumors, and autoimmune diseases such as multiple sclerosis. All of these cases appear to
be associated with an increase in the numbers of MC, which can be stimulated to secrete
various neuropeptides and neurotransmitters such as acetylcholine (Fantozzi R. et ai,
1 978).
The close proximity between the cerebral MC and the cerebrovascular organs
suggests that these cells could have important functions in controlling the integrity of the
blood-brain barrier. Secretion of vasoactive molecules could make this barrier permeable
to blood lymphocytes or pathogenic agents.
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CD251IL-2 Recepto r:
An important requirement for proliferation of mitogen or Ag-stimulated

lymphocytes is not only the production of IL-2, but also the interaction of this cytokine
with its receptor.The IL-2R is formed on the cell membrane by the noncovalent
interaction of two polypeptide chains (Greene, 1 988; Wang et aI. , 1 987). The 55Kd
protein (TAC Ag, CD25) represents one of these receptor proteins which associates with
a 70Kd protein to form the functional high affinity IL-2R . The IL-2R subunit, IL-2R a
(p55, Tac antigen, CD25), is a protein of 251 amino acids (Minami et al., 1 992 and
1 993).The gene for human IL-2R a is located as a single copy on chromosome l Op/ 1 4- 1 5
(Leonard et al., 1984 and Kuziel and Greene, 1 99 1 ). Post-translational processing of IL2R a involves glycosylation, sulfation and phosphorylation, resulting in its final MW of
55Kd (Hanisch and Quirion, 1 996). Hanisch and Quirion also reported that IL-2Ra has a
low affinity, whereas IL-2R a in association with IL-R �, or in the trimeric complex a�y,
contributes to the high-affinity binding sites for IL-2 with Kd values in the range of 1 0.10
and 1 0- 1 1 M. Expression of IL-2R a inT cells, B cells and monocytes depends on
induction by certain stimuli such as, Ag, IL- l , TNF �, mitogen or by IL-2 itself (Arima et

al 1 992; Ballard et aI., 1 989; Hatakeyama and Ta.nl.,cyuchi, 1 99 1 ).
.,

As mentioned, the effects of IL-2 on the activation of its target cells are mediated

through specific cell-surface receptors. The IL-2 receptor comprises at least three
subunits encoded by different genes. The first component to be identified, IL-2R a, is a 55
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kDa protein that binds IL-2 with a Kd of about
chain of the IL- 1 5 receptor (Theze et al.,

1 0 nm and shares homology with the

Q

1 996). The other identified subunits are IL-2R�

and IL-2Ry. IL-2� .is a 75 kDa protein containing a large intra-cytoplasmic domain of
286 amino acids. IL-2� .is shared with IL- 1 5 whereas IL-2Ry .is a

64 kDa protein that

also participates in the formation of the IL-4, IL-7, IL-9 and IL - 1 5 receptors (Theze et al,

1 996). This chain .is also critical for signal transduction via JAK-3.
The cytokine, IL-2, has multiple immuno-regulatory functions and biological
properties not only related to

T cells. Hanisch et al., ( 1 996) provided the following

evidence that suggested that IL-2 .is also a modulator of neural and neuroendocrine
function: 1 ) extremely potent effects of IL-2 on neuronal cells was discovered that
included activities related to cell growth and survival, transmitter and hormone release,
modulation of bioelectric activities; 2) IL-2 may be involved in the regulation of sleep

and arousal, memory function, locomotion and modulation of the neuroendocrine axis; 3)
the concept that IL-2 could act as a neuroregulatory cytokine has been supported by
reports on the presence in rodent and human brain tissues ofIL-2-like immunoreactivity,
IL-2-like mRNA, IL-2 binding sites, IL-2 Rex and � chain mRNA immunoreactivity and

4) IL-2 and/or IL-2R molecules mainly localize to the frontal cortex., septum, striatum,
hippocampal formation, hypothalamus, locus cereleus, cerebellum, the pituitary and fiber
tracts, such as corpus callosum, where they are likely expressed by neuronal and glial
cells.
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Elliot et al. ( 1 992) reported that T cells, obtained from patients harboring
malignant gliomas, exhibited a profOllld
l decrease in mitogen-induced proliferation. This
was presumed to be a consequence of a failure of these cells to secrete normal amounts of
IL-2 and express the IL-2R. They and others (Fontana et

al., 1 982; 1 984) report that

glioma cells are capable of diminishing lymphocyte function and may be responsible for
the marked inhibition of immune function in these patients. The finding that glioma cells
secret factor(s) that suppress the function of lymphocytes from normal subjects supports
this hypothesis (Roszman et

al. , 1 987).

Blood Brain Barrier:

Normal:
The most notable morphological difference between the
systems is the existence of a barrier that separates the
preserving the

CNS and tissues of other

CNS tissue from the blood, thereby

CNS protected environment. The blood-brain barrier (BBB) was once

considered to be a single membrane. However, it actually consists of luminal plasma
membranes, cytosol and abluminal membranes of the endothelial cells. Because of
morphological difference, for many years it was believed that the brain was an "immuno
privileged" site, possessing few if any immune elements (Fossati et

aI., 1 999). Wahl et

al., ( 1 988) described the morphological substrate of the BBB in cerebral vessels as a
continuous layer of endothelial cells with tight junctions and no or minimal vesicular
transport. He presented functional characteristics of the BBB as: a) low diffusional
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permeability for compounds, b) low hydraulic conductivity, c) high reflection coefficient,
and high electrical resistance. The consensus of a limited BBB was based on the
following: 1 ) the cerebral capillary endothelial cells that constitute the BBB differ from
those of the peripheral circulation in that they form extensive tight, impermeable
junctions between adjoining cells;

2) endothelium is devoid of fenestrations and

transcapillary channels and express a very low rate of pinocytotic activity; and 3) this
continuous barrier means that, for all but a few compounds, passage into the brain from

the circulation is determined by the solutes' lipid solubility (Greenwood, 1 990).
According to Greenwood (1 990), glucose and the amino acids that are essential nutrients
to meet the high metabolic demand of the brain are transported across the BBB in
specific transport systems that facilitate their entry into the brain..

The existence of all of these parameters are indicative of low diffusional exchange
o f water-soluble solutes and inhibition of the penetration of several mediators by
enzymatic degradation at the endothelial border

(Wahl et a!., 1 988). It is known that

lipophilic compounds can easily cross the BBB by simple diffusion, while transcellular
transport of hydrophilic solutes is made possible by facilitated diffusion and active
transport. These mechanisms, described by

Wahl et a!., ( 1 988), permit a highly selective

exchange between blood and brain and provide an optimally controlled homeostatic
environment for the brain in a pbysiological state.
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BBB Under Pathological Conditions:
In many diseases that affect the brain, the cerebral endothelium plays an active
part in the disease process with the BBB becoming disrupted. This modification can
cause a dramatic increase in vascular permeability. Consequences related to these disease
processes include vasogenic brain edema and possible development of secondary brain
damage (Greenwood,
Greenwood

1 99 1 ) .

( 1 99 1 ) postulated that increases i n BBB permeability were associated

with neoplasia, ischemia, hypertension, dementia, epilepsy, infection, multiple sclerosis,
experimental allergic encephalomyelitis and trauma. Evidence suggests that the cerebral
endothelium is under direct influence from the astrocytes (Arthur

et al., 1987). The unique

characteristics of the BBB, therefore, are due to factors released by or present on
astrocytes ( Beck

et al., 1 984). Both Arthur et al.,( 1 987) and Beck et al., ( 1 984)

considered that in certain pathological conditions it is possible that the influence of the
astrocyte and its factors are lost. This gives rise to structural changes in the endothelium
following ischemia For example, both intrinsic and newly formed capillaries are often
devoid of BBB characteristics and resemble endothelium from peripheral tissue.
Evidence also suggests that in many diseases of the

CNS, mediator substances from

damaged or activated cells can induce barrier dysfunction. Mei Liu

( 1 988) suggested that

these vasoactive compounds may originate from a number of different sources - the
blood, the cells of the CNS or from the endothelial cells themselves.
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Blood-Borne Mediators:
Schurer et aI., 1 989 have demonstrated that the blood-borne products of the Jcinin
and complement system, bradykinin and complement C3a, can increase the permeability
o f the BBB in experimental animals. Similarly, platelets, basophils, macrophages and
active T lymphocytes are cells of the blood, that according to Schurer et ai. , (1 989), have
been shown to be a major source of vasoactive compounds. T lymphocytes release
substances, such as histamine (Dux and Joo, 1 982), serotonin (Olesen, 1 985) and
leukotrienes (Black and HofI: 1 985) that disrupt the BBB.
The current study was based on the following rationale. 1) human brain tumors
progress rapidly and are almost invariably fatale despite combination therapy involving
surgery, radiation and cyto-reductive drugs. 2) Little success has been achieved
employing aggressive experimental adjuvant therapy against weakly immunogenic
human tumors. 3) Activation of lymph node lymphocytes which circulate through the

blood and enter tumors can be induced by immunization.

Chapter 2 :

PRIMARY VACCINA nON I N T HE INTRACRANIAL R T- 2 GLIOMA MODEL

Introduction
Current advances in cell biology, tumor immunology, and molecular biology has
helped rekindle an interest in tumor vaccines as our understanding of Ag processing and
presentation has evolved. Livingston ( 1 993) and Schirrmacher ( 1 995) base the
development of vaccines on three premises:

( l ) the presence o f qualitative and

quantitative differences between tumor cells and nonnal cells; (2) the immune system,
with its complex assortment of cells and cell products, provides specific and nonspecific
protection against foreign substances; and (3) the immune system can be "taught" to
recognize these differences and mediate tumor rejection by specific active immunization
using these vaccines. Our observations support the hypothesis that a primary vaccine is
able to provide some protection against RT-2 gliomas.
The first set of studies began by investigating the survival times of rats that were
vaccinated in the hind footpads (HFPs) with 4x l 06 irradiated but viable RT-2 cells. Seven
days later, the animals received intracerebral (IC) injection of viable RT-2 glioma cells.
Ten thousand RT-2 cells in S ill of phosphate buffered saline (PBS) were injected over a
33
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tlllrty minute period. Subsequently, 30% of the primed animals survived the IC challenge.
6
These findings suggested that a 10 vaccination of 4xl 0 cells per HFP provided some
protection, but there was a 70% failure rate in prolonging survival.
The second set of studies was designed to ask whether the amount of the
6
6
inoculum ( 4x1 0 irradiated cells versus 8x1 0 irradiated cells) affected survival. Data did
show that this experiment resulted in significant differences in the rate of survival and/or
length o f survival from Experiment 1 .

The RT-2 Glioma
The cell line, RT-2, was provided by Dr. G.y' Gillespie and was derived from a
glioma induced by the inoculation of the Rous sarcoma virus (Schmidt-Ruppin strain)
into the brain of neonatal Fischer 344 rats. The RT-2 glioma cells are plastic-adherent
and maintained in Dulbecco ' s Modification of Eagle ' s Media (DMEM) supplemented
with 5% fetal calf serum (PCS). Their in vitro doubling time is 1 4.5 hours.
It has been suggested and shown that immunotherapeutic approaches for
treatment of brain tumors can harness the control of a patient's immune system and direct

it towards tumor (Kruse et aI., 1 989; Merchant et aZ., 1 990). The RT-2 glioma model has
been used extensively in our lab and others, is well characterized, and shares many
features with human gliomas (Watts and Merchant, 1 992). The rat RT-2 glioma provides
a model for immunotherapy for brain tumors. A major factor of significant importance is
that the use of syngeneic RT-2 tumor cells in the syngeneic Fisher 344 rats is the
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experimental results provide a provision of a consistent genetic basis for interpretation of
results.
A synopsis of these characteristics follows. Watts and Merchant (1 992) showed
that glioma-bearing rats experienced ataxia with increasing tumor burden. These rats also
lost approximately 25% of their body weight over the course of a two week study period.
I mmunological status showed a progressive decline as well as behavioral impairments

and decreased functional activity. At seven days post tumor inoculation, they showed that
animals displayed slight contralateral paralysis and delayed response to painful stimuli
By Day 1 3 post

RT-2 implantation, most rats exhibited diarrhea and a lack of grooming.

Papilladema and periorbital hemorrhage due to increased intracranial pressure was also
demonstrated. Without

treatment,

animals died between 1 4 and 1 7 days after Ie

implantation of 1 0,000 RT-2 cells.
Seven days after RT-2 glioma implantation, histological examination of brains
revealed a small tumor with BBB permeability changes evidenced by extravasation of
endogenous IgG in the adjacent cortex immediately around the tumor. Other changes that
were demonstrated were: some of the vessels within the tumor displayed a little leakage
of the protein tracer outside the vessel wall; less extravasation ofIgG was seen at early
stages in tumor growth due to limited neovascularization of the tumor; there was no
central necrosis due to small tumor size; and) and there was limited hemorrhage within
the tumor.

36

As the glioma grew, they showed that there was no increased BBB permeability
throughout the entire tumor and adjacent brain. The glioma was greatly increased in size
at day 1 0 and 1 3 post-tumor implantation and compression of the underlying white matter
had caused ventricular collapse. Also noted was the shift of the tumor-bearing
hemisphere past midline as well as distortion of the contralateral hemisphere. Briefly, a
summation

of their findings regarding the presence oflgG in the tumor are that IgG

extravasation was observed as an intense, dark brown immuno-reactive product within
the surrounding cortex and white matter and that some of the larger vessels within the
tumor exhibited permeability to circulating IgG. However, because of the densely
organized tumor cells, the tracer was confined to the region immediately adjacent
to the vessels. They also showed that limited extracellular space within the growing
tumor prevented diffusion oflgG far into the tumor parenchyma; that the most intense
staining was seen at the growing edge of tumor at Day 1 3 ; and that as the tumor enlarged,
more edema and hemorrhage was seen within the edematous peritumoral tissue.
Primary Immunization

Since no conventional treatment for glioma is deemed curative at this time, tumor
biology, host reactions (immunogenic manipulations) and gene therapy have become a
primary focus of investigators in the neuroscience field. Approaches to cancer using
immunotherapy can be placed under the following three categories: ( 1 ) nonspecific
immunotherapy consisting of methods designed to stimulate, augment or boost the
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immune capacities o f the cancer patient nonspecifically by various means, using
adjuvants such as bacillus Calmett-Gurin (BCG),
and polynucleotides;

Corynebaclerium parvum, levamisole,

(2) active or specific immunotherapy or vaccination, referring to the

specific immunization of the patient with treated tumor cells, "tumor Ag" preparations, or
cross-reacting viral or bacterial Ags in an attempt to specifically or selectively augment
functional immune reactions; and (3) passive or adoptive immunotherapy involving the
administration of immune cells, serum, or Ags from a specifically immunized host, in an
effort to transfer specific immunity to the cancer patient. Since exposure to tumor Ags
and cytokines

in virro causes CD3+CD8+ populations of cytotoxic T lymphocytes to

develop anti-tumor activity, we wanted to generate therapeutic cytotoxic effector cells

in

vivo against the RT-2 glioma cell line. The following experiments provide a glimpse of
the usefulness and promise that manipulation of the immune system holds.

Materials and Methods:

A nimals:
Inbred female Fischer 344 rats weighing 120 to 1 40 grams and ranging in age from 4 to
months were obtained from Harlan Sprague Dawley (Indianapolis,

IN).

6

Animals are

housed in a climate controlled, AAALAC approved vivarium and were provided free
access to rat chow and water. All experimental animal procedures have been approved by
the VCUIMCV Institutional Animal Care and Use Committee.
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RT-2 Cell Line and Cell Culture:
The RT-2 glioma cell line was cultured in complete medium consisting of
Dulbecco 's Modified Eagles Medium (DMEM ) (Ci11Jco BRL, Grand Island NY)
supplemented with 1 0% Fetal Bovine Serum (FBS) ( Gibeo BRL) and non-essential
amino acids. They were maintained as adherent monolayers in culture flasks, incubated at

3 7° C in an atmosphere of 5% CO2 and 95% air and passed biweekly using 0.5% trypsin.
RT-2 glioblastoma cell line is completely lethal when implanted IC into naive syngeneic
rats. Irradiation of RT-2 cells was performed using the Cesium irradiator for I O minutes.
These cells were maintained on ice in 50 ml tubes.

Mat-B ill Cell Line and Cell Culture:
MAT-B III is a mammary adenocarcinoma cell line induced by
dimethylbenzanthracene in a Fischer

344 rat (Segaloff; 1 966).The Mat-B III tumor cell

line was cultured in complete medium consisting of DMEM (Gibco BRL, Grand Island
NY) supplemented with 1 0% FBS (Gibco BRL) and non-essential amino acids. They
were maintained as adherent mono layers in culture flasks, incubated at

3 7° C in an

atmosphere of 5% CO2 and 95% air and passed biweekly using 0.5% trypsin. Mat-B ill
cell line was completely lethal when implanted I C in RT-2 vaccinated rats. Intracranial

Tumor Implantation:
Tumor cells for IC implantation were trypsiniz.ed and washed twice with PBS and
4
a final suspension of 1 xl 0 viable cells per 5 .ul of PBS was made. Animals were
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anesthetized by an intraperitoneal (IP)injection of ketamineHCl

(6.5

(87 mglkg) and xylazine

mglkg). The scalp baIT was shaved, wiped with betadine and an incision was made

over the cranial midline. Animals were placed in a stereotactic apparatus and bregma was
located and used as a reference point for injections. A hand-held Dremel drill was used to
create a shallow depression

4 mm to the right of bregma and 1 mm posterior to the

coronal suture. Five #1 of tumor cell suspension
parietal 10be of the brain at a depth

( l x1 04 cells) was injected into the

if 3.5mm using

a Hamilton syringe and a 26-guage

needle secured to the arm of the stereotactic apparatus. The needle tract was sealed with
bone wax and the incision closed with surgical staples.

Treatment #1:
To determine if a

10 immunization with irradiated RT-2 glioma cells would

sensitize rats to reject an IC challenge of viable RT-2 cells; and, to determine if the
immunization would be tumor specific, a study was conducted to determine the survival
times of rats after receiving a

1 0 immunization in the right (R) and left (L) HFPs with

irradiated RT-2 tumor cells. There were
group as seen in Table
buffered saline

3

groups of animals with

1 0 animals in each

1 . At Day 1 , Group A (control group- I ) received sterile phosphate

(PBS) at 1 00 #1 per HFP.

(experimental group) received

Group

B

(control group-2) and Group C

4x1 06 irradiated RT-2 cells per HFPs. After one week.,

1 x1 04 viable RT-2 glioma cells were IC injected into the right cerebral hemispheres of
Group A and Group

C rats. Group B animals received 1 x 1 04 viable MAT-B III cells Ie.
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The MAT-B III cells functioned as a control to show specificity of the vaccine to the RT2 cell line. All animals were monitored for survival.

MA T-B III Cells Ie
MAT-B III cells are from a mammary adenocarcinoma cell line induced by
dimethyl-benzanthracene in a Fisher 344 rat (SegalofL 1 966). The Mat-B III cells
functioned as a control to show specificity of the vaccine to the RT-2 cell line. (refer to
Table

2 . 1 ). All animals were monitored for survival (see Figure 2. 1 ) .

Tab le 2 1 Vaccmation an d IC Ch aUenge S ch edule
.

Day 1

Group A (control group)

n= 1 0 - received PBS ( l OOJ.lVHFP)

Group B (control group)

n= 1 0 - received irradiated RT-2 cells (4x 1 0bIHFP)

Group C

o
n= l O - received irradiated RT-2 cells (4x1 0 lHFP)

(experimental groups)
Day ?

Group A

4
n=1 0 - Ie inj ection- 1 0 viable RT-2 glioma cells

Group B

4
n= 1 0 - Ie inj ection- 1 0 viable MAT-B III tumor
cells

Group C

4
n=l O - Ie injection - 1 0 viable RT-2 glioma cells
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Results
As

seen in Figure 1 , the per cent survival in Control Groups A and B was 0%. A

survjval rate of 30% was attained in the experimental Group C and this extended beyond
60 days. The PBS control group (A) showed a standard survival of l 6 days; the MAT-B
ill group (B) showed an average range of survival of 1 8 days; and the RT-2 model (C)

demonstrated 1 00% survival up to 28 days and 30% survival beyond 60 days.
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Figure 2.1 Survival data from LC. RT-2 glioma implantation.

Kaplan-Meier survival plot in which 3 groups of animals were implanted with I x l 04 RT2 glioma cells in the brain as previously described. All animals received a HFP
vaccination of sterile PBS (0. 1 ml) or 4xl 06 irradiated RT-2 glioma cells. The results are
representative plots of at least 3 independent studies.
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Treatment #2:
To determine if survival is influenced by the size of the inoculum. Experiment 2
consisted of three groups with eight animals per group as seen in Table 2. Day 1 , Group
A (control group) received 1 00 #1 of PBS IHFP. Group B (experimental group- I )
6

received 4xl 0 irradiated RT-2 tumor cells in the NN. Group C (experimental group-2)
6

received 4xl0 irradiated RT -2 tumor cellslHFP. At Day 7, IC injections of 1 04 RT-2
cells were given in the right cerebral hemisphere were given to animals in all three
6

groups. Day 1 - Group A (n= 8 ) received 1 00 #1 PBS. Group B (n= 8) received 4xl 0
6

irradiated RT-2 tumor cells Group C (n= 8) received 8x1 0 irradiated RT-2 tumor cells
Day 7- All 3 groups received IC injections of 1 04 RT-2 tumor cells in the R cerebral
hemisphere.
Ta hIe 2 2 Represen t s th e 1 °
.

vaccma ti on sch eduJ e

No. of Animals

Day

Group

1

A

8

B

8

C

8

A
B
C

8

7

an d Ie

ch a

IIenge sch edu Ie.

PBS or RT-2 Cells Received
received 1 00#1 PBS (HFP)
0

received 4x1 0 irradiated
RT-2 cells
0
received 8x1 0 irradiated
RT-2 cellsi!illl
received IC injections of 1 0 4
viable RT-2 cells in the R
cerebral hemisphere

�

Results:
As seen in Figure 2, rats in Group A and Group B were

all dead by day 1 7 post IC
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challenge with viable RT-2 cells. Experimental C showed extended survival with 30% of
these animals in the experimental group surviving beyond 60 days. In this case, the
amount of the inoculum did make a difference in extending survival of rats receiving a
total of 8xl 0 6 irradiated RT-2 tumor cells in the HFPs versus 4x1 06 irradiated RT-2
tumor cells in the NN. The experiment should be repeated using these to sites for
immunization but the amount of the inoculum should be the same.

Discuss ion:
The current forms of immunotherapy for human cancers can be broadly separated

into two major categories, 1 ) cellular immunotherapy that is preventive and the subject of
this dissertation, and 2) antibody-guided immunotoxin therapy. Any immune response

eventually mounted against malignant gliomas in vivo in response to a 1 0 vaccination is
clearly insufficient, as seen in Figure 1 , for eradication and prevention of tumor cells and
tumor development. Data reported here, using the highly immunogenic RT-2 glioma as a
primary vaccination followed by IC challenge, resulted in a 30% survival of challenged
rats. Rats challenged with MAT-B ill showed a 1 00% death, which indicated that there
was specificity of the vaccine.
These data also raise questions regarding the fate of lymphocytes generated in the
primary immune response. Primary responses ofT lymphocytes are initiated when Ag
localizes in discrete micro-environments of the lymphoid tissues. These tissues are the
peri-arteriolar lymphocyte sheaths of the spleen and paracortex of the LNs (Sprent,
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1 994). Naive recirculating lymphocytes not only perfuse these areas, but recognition of
Ag at these sites causes a selective sequestration of Ag-reactive T cells.
According to Sprent ( 1 994), the MHC-bound antigenic peptides induce T cell
trapping, such as displayed by interdigitating dendritic cells. Following trapping ofT
cells, there is a rapid proliferation ofT cells that is assisted by the influence of cytokines.
Cell expansion is a reflection of Ag concentration and affinity of the responding cells.
The proliferating cells are capable of acquiring various effector functions and are then
released into both vascular circulation and central lymphatic vessels after a period of
several days (Sprent, 1 994). These primary immune responses, however can lead to either
rapid clearance of Ag, or to an immune response of brief duration followed by a quick
loss o f the bulk of the effector cells generated in this response (Springer, 1 994). This
suggests that in 70% of our rats, the primary immune response was an immune response
o f brief duration and disappearance of the bulk of effector cells. The 30% survival of rats
in this experiment suggested that the actions of the APCs were such that the immune
response resulted in the production of effector T cells and probably memory T cells.
Direct evidence that proliferating T lymphocytes generated in a primary immune
response may be rapidly eliminated has come from studies with super-Ags. Webb et aI.,
( 1 990), Kawabe and Oichi, ( 1991), and McDonald et aI., ( 1 99 1 ) have shown that primary
immune responses to super-Ags initially involve a strong Vf)-specific proliferation
response in the spleen and LNs. This is followed by the entry of large numbers of blast
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cells into the blood and lymph. The progressive disappearance of responding T blasts is
associated with a disappearance of the APCs (Webb et ai., 1 990).
The survival and proliferation of CTL during the effector phase of the immune
response was probably critical for the elimination of tumor cells. Guiuntoli II et ai , 2002,
reported that the expansion and cytolytic function of tumor-reactive human CTL can be
enhanced by CD4+ helper T lymphocytes through co stimulatory signals that were
mediated by cell surface molecules. Their work suggested that these co stimulatory
receptors on CD8+ CTL were capable of interacting with corresponding ligands on T
helper lymphocytes that resulted in enhanced proliferation and survival of the CTL
during the effector phase of antitumor responses. These findings underline 1 ) the
importance of Ag-specmc T helper lymphocytes for regulation and maintenance of CTL
-

immunity; and 2) have implications for the design of therapeutic vaccines for cancer.

Chapter 3

PRIMARY IMMUNIZATION FOLLOWED BY SECONDARY IMMUNIZATION

Introduction
A milestone in tumor immunology was the formulation of the cancer immunosurveillance theory by Burnett in the

1 960s. This theory postulated that cell-mediated

immunity plays an important role in the control of cancer. The specific immune response
can

be divided into the humoral immune response - mediated by B lymphocytes and their

Ag recognition product immunoglobulin

and the cell-mediated immune response, which

involves T lymphocytes. T lymphocytes as a whole are a diverse group of cells that can

be broken down into the following subsets: Th cells, cytotoxic T (cT) cells and
suppressor T cells CsT). Zimmerman

et al., ( 1 996) subdivided T cells into naive, effector

and memory subsets. Naive T cells are resting cells that have not encountered Ag after
release from the thymus; whereas, effector T cells are activated cells. The presence of and
recognition o f Ag by effector

T cells, enables them to perform specialized functions with

high efficiency and without further differentiation. In Chapter 2, we found that a
survival was attained with

3 0%

a 10 vaccination only. Hence in this chapter, we investigated

survival ofrats after receiving

a 1 0 vaccination in the NN followed 14 days later by a 20

vaccination o f irradiated RT-2 glioma cells in HFPs. We theorized
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that the mechanism of
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protection against the development of tumor in the animal glioma models, post 1 0 and 20
vaccination with irradiated glioma cells, is an

in vivo stimulation of effector and cytotoxic

memory CD8+ T lymphocytes.

Materials and Methods
The materials for Chapter 3 are the same as described in Chapter 2.

Treatment #3
We wanted to determine if a 10 inoculation of irradiated RT-2 glioma cells in the
NN , followed 1 4 days later by a 20 inoculation of irradiated RT-2 cells in the

HFP would

provide protection against development of glioma and prolong survival. The experiment
had two groups of l O animals per group as seen in Table 3 . 1 . Group A (n= 1 0) was a
control group that received a 1 0 vaccination of 1 00 III of PBS per NN. At Day 1 4, this
4
group received a 20 vaccination of 1 00 III of PBS per HFP. An IC challenge Of l 0 RT-2
viable glioma cells was done on day 2 1 . Group B (n=] 0) was an experimental group that
6
received on day ] a 1 0 vaccination of 4x l 0 irradiated RT-2 glioma cells in the NN. On
6
day ] 4 , this experimental group received a 20 challenge of 4x1 0 RT-2 cells per
4
day 2 1 , all 1 0 rats received an IC challenge of 1 0 viable RT-2 glioma cells.

HFP.

At
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T a b1 e 3 1 Represents C ontro1 Group A and Experimental Group B.
.

Group

Day of Treatment

Animals

Treatment

A

1

N=l O

control group 1 0 vaccination- received 1 00 ul of
PBS in the NN;

14

N=1 0

control group - 20 vaccination received 1 00ul
PBS in the HFPs

21

N=1 0

I e challenge in R cerebral hemisphere with 1 04
viable RT-2 cells

B

1

N=1 0

experimental group; 1 0 vaccination - 4xl 0c
irradiated RT-2 cells in the NN

14

N= 1 0

experimental group; 20 vaccination - 4x I 06
irradiated RT-2 cells per HFPs

21

N= 1 0

I e challenge in R hemisphere - 1 04viable RT-2
cells

Results

As seen in Figure 3 . 1 , rats in Group A (n= l O) were all dead from tumor by day

1 7. Rats in Group B (n= 1 0) attained 1 00% survival and showed no signs of tumor at the
site one injection. These rats survived beyond 1 80 days.
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Figure 3.1. A 1 ° and 2° Vaccination with Irradiated RT-2 Glioma Cells.

1 ° vaccination with either sterile PBS or 4x1 06 irradiated
RT-2 glioma cells in the NN on Day 1 . A 2° vaccination was administered on Day 7 of
6
either PBS or 4xl 0 irradiated RT-2 cells per HFP. A Kaplein-Meier survival plot, which
Groups of animals received a

has combined the results of three independent studies, is shown. The survival of the RT-2
vaccinated group shows significant survival and protection in comparison with the non
vaccinated group.

P< 0.000 1 .
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Discussion

Vaccination had an important role in reducing the mortality that is caused by RT2 tumor. The ultimate goal of the vaccine was to develop long-lived immunological
protection, whereby the first encounter with RT-2 glioma is remembered, which leads to
enhanced memory responses that either completely prevent re-infection or greatly reduce
the severity of the disease.
The memory T cell compartment consists of both CD4+ and CD8 + T cells that can
acquire effector functions to kill infected cells and secrete inflammatory cytokines.
Effector CD4+ T cells help in B-cell responses and enhance CD8+ T cell development,
through the activation of APCs or secretion of cytokines such as IL-2, IL-4 and IL-5 .
The context i n which the T cell recognizes Ag, the abundance o f Ag and the
duration of Ag exposure are important parameters that can affect the speed and nature of
the T-cell response (Kaech

et al., 2002). The tenets ofT cell immunologic protection is

well established in that the anamnestic response that is mediated by memory CD4+ and
CD8+ T cells is more rapid and aggressive than the primary response.
Kaech

et aZ., (2002), reveal the physiological basis for the heightened recall

responses of memory T cells: "( 1 ) as a consequence of clonal expansion during the
primary infection, experiments in mice have shown that there can be a substantial
increase ( 1 000 fold) in precursor frequency of Ag-specific T cells in immune animals
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compared with naiVe animals; (2) as naIve T cells differentiate into memory T cells, their
gene-expression profile is reprogrammed by changes in chromatin structure and the
profile of active transcription factors. For example, the genes that encode IFN-y and
cytotoxic molecules, such as perforin and granzyme B, are not expressed in naive CD8+ T
cells, but are constitutively expressed in effector and memory CD8+ T cells. Elevated
levels of the messenger RNA transcripts endow memory CD8+ T cells with the capacity
to produce larger quantities of these proteins more rapidly than naIve T cells. (3) Memory
CDS+ cells express a different pattern of surface proteins that are involved in cell

adhesion and chemotaxis from naive T cells, which allow memory T cells to extravasate
into non-lymphoid tissues and mucosal sites. This enables memory T cells to survey
peripheral tissues. Recently, memory CD8+ T cells that reside in these peripheral tissues
have been termed 'effector' memory T cells, whereas those that are found in lymphoid
organs are termed 'central' memory T cells; (4) memory T-cell populations are
maintained for a long time due to homeostatic cell proliferation which occurs at a slow,

yet steady pace. The rate of this homeostatic cell division must equal the rate of cell
death, because the number of CD8+ T cells remains relatively constant over time." We
can conclude from this, that when the secondary immune response in this experiment

came into contact with the given Ag, it differed from the response produced after the first
antigenic encounter as seen in Figure 2. The capacity to produce a secondary immune
response or anamnestic response persisted long after the first encounter or contact with
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the Ag. Thus it is the increased number o f Ag-specific T cells, and their faster responses,
anatomical location, and longevity that explain how memory T cells controlled long-term
protective immunity in this vaccination treatment.

Treatment # 4:
We wanted to determine

if a heightened

immune response occurs at the site ofIC

challenge in immunized rats that received a 2° vaccination. Contrast and comparison of
the prophylactic immune response to an endogenous immune response was performed at
days

3, 5 , and 7 post I C injection using three color flow cytometry and histology. Day 5

showed significant changes in the presence of lymphocytes

in the

vaccinated versus the

control animals as seen in the tables of FACs analysis and histograms that follow.

Methods: FACS Analvsis of Infiltrating Leukocytes
RT-2 tumor tissue was excised and forced through a 70 pm nylon cell strainer
(Fischer Scientific) using the butt of a sterile 3 cc syringe plunger. Cell suspensions were
washed three times with cold

5 % PBS-PBS. Viable leukocytes were enumerated using a

hemacytometer and trypan blue exclusion and then were treated with a battery of
fluorescently conjugated mAbs for FACs analysis. l xl 06 cells were stained in V -bottom,
96-well microplates (Costar Brand, Fischer Scientific) in a volume of 5 0 pI of 5% FBS
PBS. Cells were suspended in a cocktail containing three monoclonal antibodies
(mAbs)coupled to FITC, PE or biotin and incubated in the dark for

30 minutes on ice.
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The mAbs were isotype controls, CD3E, CD4, CD8B, His 48 and CD45
(pharmingen, San Diego, CA). After the primary Ab incubation, the cells were washed
twice and incubated in streptavidin-PerCP (Bectin Dickenson Immunocytochemistry
Systems, San Jose, CA) using a 1 :250 dilution for 30 minutes on ice. Finally, the cells
were washed twice in a volume of SOp] of 5% PBS-PBS, fixed in 1 % paraformaldehyde
and stored at 4° C until analysis was done. Three color flow cytometry analysis was
performed using a Coulter Epics XL-MCL flow cytometer.

Table 3.2: FACs Analysis of Cell Populations of Vaccinated Animals at Day 5 Post

. ted
Ie Challenge. Day 5 Vaeema
Region ID

Cl
C2
C3
C4

-

CD3/4/8

%
2.49
2 . 84
93.1
1 . 54

Count

21
24
787
13

Table 3.3: FACs Analysis of Cell Populations of Non-Vaccinated Animals at Day 5
P ost IC Ch a IIenge. Dl!Y 5 C on tro1 - CD3/4/8
Region ID

Cl
C2
C3
C4

%
1 .05
2.59
95 .9
0.49

Count

13
32
1 1 85
6
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Figure 3 .2 Normal

FACS stainmg for Tables 3.2 and 3.3 of T lymphocytes at Day 5 post

IC challenge with viable RT-2 glioma cells. Lymphocytes were isolated from the brain
for CD3€:, CD4 a� T lymphocytes and CD8 a� T lymphocytes in experimental animals
(vaccinated) and control animals (non-vaccinated) animals.
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Preparation and Staining of Brain Tissue From Day 1 and Day 5 Tumors

Fixation of tissues was done by immersion with glutaraldebyde. In general, the
tissue was fixed in 3 % glutaraldebyde on a 0. 1 M sodium pbosphate buffer at 4° C and at
a pH of 7 .2-7.4 overnight. Tissue was then washed in 0 . 1 M sodium pbosphate buffer
witb 2 changes, 5- 1 0 minutes each. Tissue was postfixed witb 2% osmium tetroxide in
the 0 . 1 M buffer for 1 hour. This was followed by washing for 5 minutes with the 0 . 1 M
sodium phosphate buffer. Debydration with a cold ethanol series followed. Vials were
placed on a shaker to aid in dehydration. Ethanol series consisted of : 1 ) 50% ethanol for
5 minutes at 4° C; 2) 70% ethano l for 5 minutes at

4° C, 3) 80% ethanol for 1 0 minutes at

4° C; 4) 90% ethanol for 1 0 minutes at 4° C; 5) 1 00% ethanol for 1 5 minutes each. three
cbanges at room temperature; and 6) propylene oxide for 20 minutes each, three changes,
at room temperature. This step was followed by infiltration of the tissue with a half-and
- half mixture of propylene oxide and Epon resin for 8 hours overnight. Samples were

placed on a shaker to facilitate infiltration. The previous infiltrate was replaced with pure
Epon resin and infiltration was done on a shaker for 8 bours. Embedding tissue in beem
capsules and addition of resin followed. Beem capsules were placed in tbe oven at 60° C
for 2-3 days. Thick section were cut and slides stained witb hematoxylin and eosin
(H&E) or toluidine blue by Ms. Judy Williamson of the Department of Anatomy and
Neurobiology.
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Results:

Based on our results in Treatment # 4, we decided to look at the histology of the
area of brain parenchyma surrounding the needle track after Ie injection ofRT-2 tumor at
days 1 and 5 . We believe that 24 hours post Ie injection an immune response is mounted
against the tumor cells. Day 1 and day 5 thick sections were stained with toluidine blue or

H&E. One animal per time-point was harvested for histology. Day 1 histology
demonstrated significant numbers of red blood cells (RBes) in the brain parenchyma at
the site of the needle tract which was expected. At the same time, significant numbers of
neutrophils were seen, not only in the brain tissue ,but within the vasculature. This acute
inflammatory response at a site of injection would be expected due to the damage done to
the brain parenchyma by the needle alone.
Day 5 histology demonstrated the presence of monocytes in the blood vessels
(Figure 3.3), rolling along the luminal walls of blood vessels, tethering to the blood
vessel wall and diapedesing through the endothelial cells into the brain parenchyma.
Other cells of the immune system seen in this tissue were lymphocytes and mast cells.

Mast cells were both granulated (Figure 3 .4) and degranulated (Figure 3 . 5 ) . Within the
glioma cells of the tumor, many mitotic figures were seen in different stages of mitosis
(Figure 3 .6). Necrotic area within the tumor bed is seen Figure 3 . 7 . Macrophages in the
brain parenchyma are also detected filled with phagocytosed hemosiderin (Figure 3 . 8).
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Figure 3.3 Histogram of Monocytes in Day 5 RT-2 Tumor
The histology demonstrates the presence of monocytes in the lumen of a blood vessel.
Tissue was stained with Toluidine Blue; magnification 20X. Rolling monocytes are
indicated by a thick arrow; and tethered monocytes by a narrow arrow.
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Figure 3.4 Histogram of G ranulated M ast Cells

The histology demonstrates the presence of granulated mast cells located outside the
lumen of a blood vessel T issue was stained with toluidine blue and magnification was
20X. Mast cells are indicated by arrows.
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Figure 3.5 Degranulating Mast Cells in Neural Parencbyma

The histology demonstrates the presence of degranulating mast cells located in brain
parenchyma. Tissue was stained with H&E; magnification I OOX. Degranulated mast cells
are marked by arrows.
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Figure 3.6 M itotic Figures in Tumor Tissue

Mitotic figures are numerous in tumor tissue. The arrow marks a mitotic figure present in
this histogram. The tissue was stained with toluidine blue;

magnification is

l OOX.
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Figure 3.7 Necrotic Tissue within Tumor Bed

This histogram shows areas of necrosis within the tumor due to loss of angiogenesis.
Tissue was stained with H&E; magnification l OX. The necrotic area is demarcated by
asterisks.
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Figure 3.8 Hemosiderin-filled Macrophages. This is a histogram of macrophages
containing phagocytosed red blood cells and the by product - hemosiderin. Tissue was
stained with H&E. Magnification is 1 00X Arrows are used to point out specific
macrophages, but the hemosiderin-filled macrophages primarily fill the field.
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Discussion:

There bas been tremendous interest in the potential for immunotherapeutic
manipulation of human brain tumors, and numerous studies have been performed to
determine whether human brain tumors express Ags recognized by the immune system in
the host of origin. As a result of those studies, a general consensus bas been reached that
human brain tumors are not antigenic/immunogenic. The difficulty with human studies is
that there are too many unknows: 1 ) it is not known whether human gliomas are

antigenic; 2) whether the assays that were employed were appropriate for detection of
antitumor responses; and 3) whether tumors progressing in the brain would induce
detectable systemic immune responses even if the tumors were antigenic. The rationale
for the current study was that some of those issues needed to be addressed under
conditions where the number o f unknowns was reduced. Thus, our studies were
conducted to determine whether a relatively well defined experimental glioma that was
1 00% lethal and known to induce detectable specific cytotoxic responses, would induce
peripheral immune response when challenged in the brain. This work provided further
support to the approach of developing methods of immunoprophylaxis of weakly
immunogenic lines and human brain tumors.

Chapter 4

MEMORY LYMPHOCYTES FACILITATE SURVIVAL

Introduction

Immunological memory manifests itself as an accelerated and elevated response
to a second stimulation by the same or closely related Ag (Mullbacher, 1 994).
Establishment of long term memory underscores all protective vaccination strategies.
One of the characteristics of an immune response is the acquisition of memory which
focuses on establishment of long-term memory in the absence of constant antigenic
challenge. We used rats that survived tumor challenge in Chapter 3 . These data are well
represented in our experimental model using a 1 0 and 20 vaccination in RT-2 glioma
challenged rats that have survived beyond 1 80 days post first IC challenge and were then
rechallenged in the left contralateral hemisphere. We hypothesize that these methods
were able to generate long-term Ag-specific cytotoxic T lymphocytes. These T cells were
long-lived lymphocytes involved in the experimental rats surviving beyond 60 days after
I C challenge and this was attained without Ag repriming. These observations suggested
that T cell memory is long-lived in the absence of RT-2 tumor Ag.

M aterials and Methods
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Animals and the RT-2 cells were prepared as mentioned in Chapter 2.

Intracranial Tumor Implantation
Tumor cells for IC implantation were trypsinized and washed twice with sterile

PBS. Viable cells were identified by trypan blue exclusion, enumerated on a
hemacytometer, and a final suspension of I xl 04 viable cells per 5 iiI of PBS was made.
Animals were anesthetized by an intraperitoneal inj ection ofketamine'HCI (87 mg/kg)
and xylazine (6.5 mglkg). The scalp hair was shaved, wiped with betadine and an incision
was made over the cranial midline. Animals were placed in a stereotactic apparatus,
bregma was located and used as a reference point for inj ections. A hand-held Dremel

drill

was used to create a shallow depression 4 mm to the left of the sagittal suture and 1 mm
posterior to the coronal suture. Five iiI of the tumor cell suspension

(I xl 04 cells) was

injected into the parietal lobe of the brain at a depth on .5 mm using a Hamilton syringe
and a 26-gauge needle secured to the arm of the stereotactic apparatus. The needle tract
was sealed with bone wax and the incision closed with surgical staples.

Methods of Determining Immunological Memory

Treatment #5:
To determine if immunological memory (long term memory) had been established
in long term survivors. Group B animals from Table 4. 1 , that survived beyond 1 80 days
after IC challenge of viable RT-2 glioma cells, were rechallenged in the contralateral left

76

hemisphere

with RT-2 tumor cells. Group A (control group) (n=1 0) were unvaccinated

animals that received RT-2 tumor cells in the left cerebral hemisphere.
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T able 4 1 Long Tenn Merom'" in Experimental Animals
Group
# of Animals
Treatment

Survival

A

n= 1 0 (control)

IC challenge
1 04 RT·2 cells

0%

B

n= 1 0 (experimental)

I C rechallenge
1 04 RT-2 cells

1 00%

.

Results:
The control Group A, showed 0% survival. All of Group A ( control rats) died by
Day 2 1 post implantation. The control rats had received sterile PBS as a vehicle instead
of RT-2 glioma cells. Results o f rechallenge in the left hemisphere showed 1 00% survival
for Group B experimental animals from Table 3 . 1 . These animals survived beyond 60
days.

Discussion:
Peripheral T lymphocytes can be classified into two groups: naive and memory T
cells. The focus of this study was to examine the duration ofT cell memory in long-lived
rats. The ability of a T cell to recognize a specific peptide epitope in the context o f MHC
molecules by APCs from tumor cells is provided by its T cell receptor. The interaction
between T cell receptor and the Ag-MHC triggers proliferation and clonal expansion of
specific T cells. Some of the progeny of the Ag-responsive T cells develop into Agspecific memory T cells. This subpopuIation of T cells is maintained within the host and
provides immune surveillance. In the event of reactivation by subsequent re-exposure to
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the tumor, specific memory T cells become activated and c10nally expand with greater
magnitude than during the initial response. It is generally accepted that specific immune
T cell memory persists after an encounter with an Ag and may help to protect the immune
host against subsequent exposure to that pathogen.
The experiments performed in this chapter suggested that specific immunity was
induced by 1 0 and 20 vaccinations with viable irradiated RT -2 glioma cells in HFPs and
the NN . The first IC challenge was in the right cerebral hemisphere. The experimental
rats that survived were rechallenged 1 80 days beyond the first challenge in the left
cerebral hemisphere. Control rats died between days 1 6 and 1 8 after I C challenge with
tumor cells. 1 00% survival was seen in the left cerebral hemisphere challenged rats. We
have reported on a series of experiments that suggested that immunological memory in
rats that received multiple vaccinations with the immunogenic RT -2 glioma cell line
could be developed and persist. In the first experiments, rats vaccinated by subcutaneous
injections of RT-2 cells were challenged in the right cerebral hemisphere. The
immunological response was specific and these animals remained protected after a
rechallenge with RT - 2 tumor cells in the left cerebral hemisphere. This work provides
further support to the approach of developing methods of imrounoprophylaxis to treat
weakly immunogenic lines and human brain tumors.

Chapter 5:

MEMORY LYMPHOCYTES PROTECT AGAINST THE DEVELOPMENT OF
RT-2 GBMS

Introduction

Active, specific immunotherapy with anti-cancer vaccines offers the possibility of
stimulating the intrinsic immune response of a patient to his or her tumor, with the
development of long-term immunologic memory through helper and cytotoxic T cells.

This vaccine may assist prophalactically in the protection of tumor development and
rejection of existing tumor cells. It may also help in surveillance against their reemergence. A draw back to some experimental studies may be seen in the fact that
vaccination-based immune therapy for cancer must be shown to work in the presence of a
pre-existing neoplasm In contrast to this type of immune treatment, we want to address
the use of classical vaccination strategies which are preventive.
These experiments examined the use of various leukocytic suspensions, from the
spleens of 1 0 and 2 ° vaccinated rats that had survived for more than 2 1 0 days, as
vaccines. Seven days prior to harvesting the spleens, animals received a booster of 1 0 4
irradiated RT-2 glioma cells in the right hind flank.
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Materials and Methods

Animals and the RT-2 cell line were treated as mentioned in Chapter 2.

Treatment #6:
To deplete various lymphocytic cell populations from spleen cells o frats that
received a 1 0 and 20 vaccination at least 2 1 0 days prior to harvesting spleens. Splenocytes
were selected for transfer because of convenience versus use of lymph nodes. Table 5 . 1
gives a breakdown o f leukocytic makeup by % as determined by Dr. Martin Oraf.

Table 5.1 Percent makeup of leukocytic cells in spleen

Leukocytic Cells

Percentage

B Lymphocytes
+
CD4 T Lymphocytes

35%
25%

CD8+ T Lymphocytes

1 0%

Natural Killer Cells

1 0%

Monocytes

1 0%

Others

5%

The purpose was to examine and determine which effector and long-term memory

cells were necessary for transfer to provide protection to naive rats before IC challenge
with viable RT-2 glioma cells. The spleen-donor rats (n=6) received a booster of 1 04
irradiated RT-2 glioma cells delivered in sterile PBS in the right hind flank to up-regulate
the secondary immune response.
Seven days post hind flank injection, spleens (n=6) were harvested from the
vaccinated rats. To obtain cells, spleens were aseptically minced and pushed through a
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nylon mesh by use o f the butt of a plunger from a sterile 3 ml syringe. The leukocytic
population was pooled and consisted of the following groups as seen in Table 5 .2. Group

1: T and B cells together as a passive transfer of a whole cell suspension; Group 2: CD4+
T cell-depleted suspension; Group 3 : CD8+ T cell-depleted suspension; Group 4: pan T
cell-depleted suspension; and Group 5 : sterile PBS (control group). Pmity of cells
transferred was 90%. The number of cells transferred was 4xl 08 per group. For future
studies, we will alter the numbers of the various lymphocytes (increase or decrease)
transferred accordingly.
Twenty four hours after receiving an IP injection of a particular cell suspension or
PBS, experimental and control rats received IC injections of viable RT-2 cells ( l x l 04) in
the right cerebral hemisphere. The animals were observed for survival.

Results:
Group 1

whole cell suspension

=

suspension

=

=

2/3 rats survived. Group 2

3/3 rats succumbed to tumor. Group 3

2/3 rats survived. Group 4

survived. Group 5

=

=

=

pan T cell-depleted cell suspension

sterile PBS control

=

1

3

4
5

�ension
whole cell sus

3

CD4+ T cell-depleted

3

CD8+ T cell-depleted

3

pan T cell depleted

3

sterile PBS

.J

..,

CD4+ T cell-depleted

CD8+ T cell-depleted suspension
1 /3 rats

=

3/3 rats succumbed to tumor. See Table 5 .2.

.
T a ble 5 2 D epletlOn
I ·
StU d·les an d S UrvIVa I
N- 3
Animal Survival
Cell Suspension
Groups
2

=

2

0

2
1
0

Deaths
1

Days Survived
30 Days

3

20 Days

2

30 Days

1

.,

.J

30 Days

1 7 Days

=
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Discussion:

A central observation in immunology is the finding that upon a secondary contact
with a given Ag, the immune response obtained differs from the response produced after
the first antigenic encounter. The secondary response that produces effector/memory T
lymphocytes persists long after the first encounter with Ag. This memory property of the
immune system, together with two other characteristics, specificity and diversity, makes
the immune system an attractive biological entity to investigate prophylactic treatment by
use of vaccines to prevent development of or treatment of brain tumors. The morbidity

and mortality caused by infectious diseases has been reduced by the important role of
vaccination. The ultimate goal of vaccines is to develop long-lived immunological
protection, whereby the first encounter with a pathogen is remembered. This leads to
enhanced memory responses that either completely prevent re-infection or greatly reduce
the severity of the disease. It has been well established that the anamnestic response that
is mediated by memory CD4+ and CD8+ T cells is more rapid and aggressive than the
primary immune response (Kaech, et al., 2002). This faster T-cell response can control
secondary infections quickly and fully eliminate the pathogen. In our previous
experiments based on mT cells, the emphasis was placed on CD8+ cytotoxic lymphocytes
for long-term survival
However, in this last experiment that involved depletion studies of CD4+ T cells
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and CD8+ T cells in cell suspensions created from harvested spleens of long-term
survivors to RT-2 glioma challenge, CD8-depleted cell suspensions given to rats
followed by IC injection of viable RT-2 tumors demonstrated long term survival. The
suspension that was CD4-depleted was not able to protect against the development of
RT-2 tumor and ultimate death. These rats did survive longer than naive rats that received
IC challenge only, but they finally succumbed to tumor. The results of this experiment
suggested that the presence of transferred memory CD4+ T cells played a significant
immunological role required to provide protection against IC tumor challenge with viable
RT-2 glioma cells. This is in contrast to the lack of survival seen in animals that received
CD8+ T cells and no CD4+ T cells in the cell suspension.
The results of this experiment suggested that the presence of memory CD4+ T
lymphocytes were required for protection against a challenge of viable RT-2 glioma cells.
The protective mechanism could possible have been that CD4+ T cells were capable of
production of the cytokines IL-2 and IL-4.
The production of these cytokines created a division of CD4+ T cells into two
separate entities. T lymphocytes are divided into Th- I cells that are responsible for
production of IL-2, INF-y, and IL- 12. Th-2 cells are responsible for the secretion of IL-4,
IL-3, IL-5 and IL-6.These cytokines play a pivotal role in the communication network of
cells. Pleiotropic functions associated with the IL-4 cytokine was first described to
enhance DNA synthesis of purified resting mouse B cells (Topp et al.,1 995). Topp et al.,
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1 995, suggested that the following cell lines were involved in the production ofIL-4:

CD4+ T lymphocytes and to a lesser extent by mast cells and human tumor-associated
natural killer celIs.

CD4+ T cells are pivotal in the immune response in that they control

the development and activation ofB lymphocytes,

CD8+ T cells, macrophages, and other

inflammatory celIs (Bunce and Be1l, 1 997).
Functional properties of IL-4 include ( 1 ) activation of resting B celIs, (2)
enhancement o f IgE production in activated B lymphocytes, (3) an increase in expression
of the low-affInity receptor for 19E,
activation of cytolytic

(4) a co-stimulant for resting T celIs, and (5) their

CD8+ T lymphocytes.

A number of studies have examined the ability of naive and memory CD4+
to synthesize cytokines after activation. Similar observation on
performed but observations suggest that naive and memory
synthesize cytokines, but to a lesser extent than the

T cells

CD8+ T cells have been

CD8+ populations can

CD4+ population (Akbar, 1 99 1 ) .

According t o Akbar, 1 99 1 , IFN-y, IL-3 and IL-6 are preferentially synthesized by the

CD4+ memory T cell population rather than by the naive celIs.
These results strongly indicate that

CD4+ T cells were required for long term

survival. These cells were a mixed bag. Therefore, three possibilities existed: 1 ) a
humoral response promoted by

CD4+ T cells; 2) CTL response promoted by CD4+ T

cells; and 3) presence of cytotoxic

CD4+ T cells. Our primary focus was number two.

The data presented here can be interpreted in a number of ways, but a hypothesis
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which incorporates our findings is the lack of induction of effective antitumor reactivity
against parental RT-2 cells in a CD4-depleted cell suspension. This could be due to a
paucity of memory helper cell function, as welJ as a consequence of suppressor factors
expressed by tumors. The ability of these rodents to survive beyond 20 days, possibly
represents an attempt by mCD8 + cytotoxicT cells to perform in a cytotoxic role.
However, without CD4+ effector/memory T cell help, the numbers of mCD8+ cytotoxic T
cells probably declined along with production ofIL-2. This reduction in IL-2 could
inhibit the activation of naIve T cells to become a large CD4 and CD8 effector
population. This, along with tumor suppressor factors, had a potential significant effect
allowing tumor to escape the cytolytic activities of CD8+ lymphocytes.
The mechanism(s) by which CD4+ T cells contribute to the initiation and
persistence of CD8+ T cell responses remain incompletely defined. Until recently, CD4dependent help for CTL responses was thought to result primarily from the production of
IL-2 to support activation of CD8+ T cells (Wagner et al., 1 980; Keene, 1. and Forman J.,
1 982).

An

additional mechanism for the provision of help in which CD4+ T cells interact

with APC in a CD40-dependent manner to "condition" the APC for effective activation
of CD8+ T cells has been recently demonstrated ( Ridge, 1. et al., 1 998; Bennett, S. et al.,
1 998; and Schoenberger, S. et al., 1 998).
In some cases, CD4 help is necessary to initiate CTL responses. However, CD8+
T cells can produce their own IL-2 response to co stimulation to drive activation in the
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+
absence of CD4 T cells (Azumi, M.
Deeths, M. and Mescher, M.,

et ai., 1 992; Harding, F. and Allison, J., 1 993; and

1 997). A CTL response occurred in the absence of help but

the response only persisted if CD4-dependent help was available. This was true in a
number of models of virus infection, tumors, and autoimmunity

(Tham, E. et ai.,

2002).

+
This suggested that different mechanisms might operate at differing stages of CD8 T cell
activation, differentiation, clonal expansion, and survival.

Tha.m. E., et at., (2002) demonstrated that if IL-2 was absent 3 days after the
+
activation response in CD8 lymphocytes was initiated, the cells lost the ability to make
further IL-2 in response to Ag and co stimulatory ligands, and clonal expansion ceased.
They described this non-responsiveness as resembling the "anergic" state originally
+
described for CD4 T cell clones following TCR engagement in the absence of
+
co stimulation. In the CD8 CTL population, it was distinct, in that it occurred following

full stimulation through both the TCR and co stimulatory receptors. Tham, E. et at. ,
+
(2002) have termed this state of CD8 T cells "activation-induced nomesponsiveness"

(AJNR) to distinguish it from the classical

anergy that occurs when T cells receive just

one signal. Further examination resulted in the demonstration that the AINR state was
reversed if continued proliferation was supported for a short time

( 1 -2 days) by provision

+
of help in the form of IL-2. After this, the CD8 T cells regained the ability to produce
IL-2 and continued to respond to Ag in an autocrine-driven manner for prolonged times

(Tham, E., et a/., 2002).
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In conclusion" helper-independent initiation of CTL responses have been
demonstrated in numerous models examining virus infection" tumors, and autoimmunity
but these responses have often failed to persist in the absence of CD4+

T cell help. NaIve

T cells responded to Ag and co stimulation by producing IL-2 to drive their initial clonal
expansion" but within a few days the cells became AINR. They could still be signaled
through the

TCR to carry out effector functions but could no longer produce IL-2 to

sustain expansion. However, the

CTL could continue to proliferate if provided with IL-2.

This suggested that the basis for the requirement for
effective

CTL responses in many instances.

CD4+ T helper cells is to sustain

Chapter 6

GENERAL DISCUSSION AND LITERATURE REVIEW

The successful application of immunological methods to the diagnosis and control
of clinical infectious disease during the 1 9th century had a resounding influence on the
reach of medical aspirations (Hewitt, H., 1 982). It fostered a hope that soon hardened into
conviction that human malignant disease would eventually yield to similar approaches. In
the 1 800s, physicians noticed that tumors sometimes regressed in cancer patients who
contracted bacterial infections. Therefore, the clinical support for the idea that the
immune system might restrain the development of cancer emerged. William B. Coley, a
surgeon at Memorial Hospital in New York City from 1 892 to 1 936, dedicated his life to
creating therapies based on this observation (Old, L. , 1 998) These treatments are now
considered immunotherapies because they aimed to attack disease with the body's own
defenses that brought about complete tumor regressions in some individuals. Deliberate
attempts were made by him to infect cancer patients with bacteria He later developed a
vaccine consisting of killed bacteria to prompt a tumor-killing response. However,
because the results were unpredictable, they were not widely accepted.
During the 20th century, the search for oncogenic agents and exploration of
immunological aspects of clinical cancer have persisted. In the early decades of the 20th
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century, experimental cancer research was confined to the use of allo-grafted animal
tumors. The high frequency of induced or spontaneous regression sustained the concept
ofturnor immunity. By the 1 920's it had been disclosed that autochthonous animal
tumors displayed no such phenomena, and the subject of clinical tumor immunity was
considered closed ( Leitch, A., 1 920). In 1 943 it was reopened; Gross had demonstrated
that xenografts o f a chemically induced tumor were immunogenic (Gross, L., 1 943).
However, the repeated demonstration during the 1 950's, that animal tumors were of
spontaneous origin, invariably failed to display the immunogenicity shown by nearly all
chemically induced tumors was ignored (Foley, E., 1 95 3 ; Prehn, R., 1 957; and Revesz, L.
1 960).
In 1 965, ROllS (Rous, P., 1 965), a pioneer of viral oncogenesis, used the occasion
of his Nobel address to warn against generalization of a concept of viral oncogenesis
beyond the meager evidence supporting it. Cancer-causing viruses were not, he said, an
"Open Sesame!" to the cancer problem (Hewitt, H. , 1 982). Proponents of a topic that was
confidently flourishing previously came to write discouraging titles as ''Back to the
drawing board . . . " ( Alexander, P., 1 977), "The questionable immunogenicity of certain
neoplasms" (Weiss, D., 1 977) " . . . non-rejectability of spontaneous tumors . . . ( Klein, G.,
and Klein, E . , 1 977); and "The case history of Mr. T.!.

-

Terminal patient or still

curable?" (No ssal, G., 1 980). Still , the link between immunity and cancer remained
frrmly fixed in the minds of many people. During the 1 960s and 1 970s there was wide
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acceptance of the "immunosurveillance" model put forth by Lewis Thomas of New York
University and MacFarlane Burnett of the Hall Institute in Melbourne, Australia (Old, L.,
1 998). This theory held that the immune system constantly seeks out and destroys
emerging cancer cells. Tumors, it proposed, arise when this policing mechanism failed.
Because accumulating evidence suggested that the immune system attacked only tumors
caused by viral infections and this accounted for only a small number of tumors, the
theory appeared flawed.
Coley' s approach to cancer therapy was described as nonspecific: it strengthened
the overall activity o f the immune system instead of selectively arousing those elements
most able to combat cancers. During the last century, scientists developed a range of
other nonspecific immunotherapies - e.g. Bacillus CaImette-Gurin, or BCG as a vaccine
to treat bladder cancer (Old, L., 1 998). Although this vaccine illustrated the potential of
non-specific immunotherapies, it acted locally, provoking inflammation only in the
bladder. Most cancers become lethal because they spread and give rise to tumors at a
distance. To eliminate these growths, immunotherapies had to

be capable of seeking out

incipient tumors in all parts of the body. To accomplish this, many research oncologists
turned in the 1 970' s and 1 98 0 ' s to molecules the body produced in response to viral and
bacterial infections, now called cytokines, to help orchestrate the defense response. The
cytokines included such proteins as interferons, interleukins, and tumor necrosis factor.
Extensive clinical testing of this nonspecific approacb dampened enthusiasm because
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relatively few patients appeared to benefit from cytokine therapy alone (Old, L.,
1 998). Cytokines have proven more valuable in combination with one another or with
other treatments.
The discovery of antibodies at the end of the 1 9th century provided the means to
search for such cancer-specific Ags and later opened the way for extensive studies of
antibodies as potential immunotherapies for cancer (Old, L., 1 998). Antibodies are a
critical component of the immune system and circulate in the blood and bind to foreign
Ags. Therefore, they are able to mark Ag-bound invaders for destruction by scavenger
cells called macrophages, by other cells and by special blood protein components,
collectively called complements.
I n 1 975, the search for Ags became easier. This was made possible by the
discovery made by Cesar Milstein and Georges J. F. Kohler of the University of
Cambridge (Old, L., 1 998). These researchers demonstrated that Ab-producing cells
could be made to survive indefinitely if they were fused with cancer cells. This technique
enabled scientists to produce unlimited supplies of identical Abs, because any given Ab
producing cell produces only a single species of Ab. This method profoundly effected
cancer immunology for several reasons. First, it provided a powerful new method to
search for cancer antigens. Secondly, defined Abs could be produced in sufficient
amounts to put Ab-based therapies to the test (Old, L., 1 998).
Monoclonal antibodies have revealed a large array of Ags that exist on human
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cancer cells. However, virtuall y all these Ags are also found on normal cells. These
normal cells might be damaged by an Ab-based therapy. This overlap does not preclude
their use as therapeutic targets for several reasons: the Ag in normal tissues may not be
accessible to blood-borne antibodies; the cancer cells may express more Ag than normal
cells do; and antibody-induced injury of normal cells may be reversible. In the Ab-based
vaccines discussed, the injected Ab is derived from an animal. The treatment is
considered passive immunotherapy: the immune molecules are given to patients, who do
not produce them on their OWD. A vaccine, however, is deemed active immunotherapy
because it rouses an immune response in the individual who needs protection. The
technology of Ab production gave rise to high expectations as well as to premature and
unrealistic assertions about Abs as "magic bullets" (Old,

L., 1 998).By recognizing

specific Ags, it was hoped that monoclonal Abs would home in on cancer cells and
trigger an immune attack that destroyed the target cell but ignored normal cells lacking
the cancer Ags. Many expected that these bullets would be more deadly by loading them
with toxic chemicals; the Abs would carry the toxins directly to the tumor, where the
poisons would kill cancer cells. At first the technology was declared a :failure. The reality
of the situation was fur more positive. The concept remained sound, and slow, steady
progress has been made in developing Ab therapies. Today, Abs can target cancer cells
and act on other cell types and molecules necessary for tumor growth. Antibodies can
neutralize growth-factors chemicals needed by tumor cells and their blood supply and
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thereby inhibit a tumor' s expansion. Antibodies can also target the stroma, the connective
tissue between tumor cells

(Old, L., 1 998). This and other Ags that mark tumor stroma or

blood vessels have become attractive targets to researchers devising Ab-based therapies.
As previously mentioned, tumors of the CNS are poorly responsive to the three
modalities of conventional anticancer therapy: surgery, radiation, and chemotherapy.
However, since the demonstration of immunogenicity of chemically induced tumors in
mice, it has been the goal of tumor immunologists to develop novel approaches to cancer
therapy based on manipUlating antitumor immunity (prabir, K..

et aZ., 1 992). Some of the

strategies presented by these authors include (a) active specific immunotherapy with
autologous or allogeneic irradiated tumor cells or their extracts in the presence of
adjuvants,(b) infusion o f large doses of interleukin-2 (IL-2) with or without lymphokine
activated killer (LAK) cells, and (c) adoptive immunotherapy involving

in vitro

activation and amplification of tumor-infiltrating lymphocytes followed by their infusion
into a tumor-bearing host. Clinical trials employing these approaches have been
conducted. The use of immunotherapy as a clinical tool has been an area of enthusiasm
and intense investigations.
Adoptive immunotherapy, whereby immunoreactive cells with antitumor activity
were transferred into the tumor bed at the time of debulking, was an approach for
potential treatment of high-grade gliomas. With the advent of recombinant DNA
techniques, recombinant IL-2 (rIL-2) was available in sufficient quantity to allow the
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generation of greatly expanded numbers of activated lymphoid cells for therapy (Kruse

et

al., 1 989).
Lillehei,

K. et al., 1 987 began clinical trials that involved intratumoral

implantation of both preparations of lymphocytes, together with rIL-2, in patients with
recurrent, high grade gliomas. The lymphokine activated killer (LAK) cells and
autologous-stimulated lymphocytes (ASL) were successfully generated from the PBL of
brain tumor patients.
Kruse

et al., 1 989 described two separately activated preparations of cells,

derived from peripheral blood to use therapeutically against brain glioma. One
preparation was widely known as lymphocyte activated killer cells. The other preparation
was termed autologous-stimulated lymphocytes. These are lectin-responsive and
combinant IL-2-responsive cells. Clinical researchers have reported the use of LAK cells
against brain tumors (Jacobs, S.

et al., 1 986 and Merchant et aI., 1 988). Others have

reported the similar use of ASL (Ingram, M.

et al., 1 987; and Ingram et aI., 1 987). Two

separate studies examined the capacity o f PBL obtained from glioma patients to respond
to PHA and rIL-2 stimulation. Yoshida

et al., 1 987, concluded that PBL from patients

with malignant brain tumors produced a level of IL-2 lower than that of normal control
subjects because of the decreased number of IL-2 producing T cells. PHA-activated PBL
from both responded equally well to rIL-2. Elliot

et al., 1 987, also found that rIL-2 did

not improve the PHA responsiveness o f PBL from patients who had not received
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radiation, steroids, or phenytoin. Kruse et ai. ' s, 1 989 data showed that there was a
statistically significant difference in the short-term cytotoxicity against all targets of brain
tumor patients' PBL stimulated with rIL-2 alone (LAK.) versus those stimulated with
PHA and rIL-2 (ASL) . They have found that in long-term cytotoxicity assays this
difference disappears. Kruse

et aI., 1 989, suggested that different types of activated cells

were responsible for the target cell lysis, and that they perhaps killed in a mechanistically
different fashion. The difference may have been due to the fact that LAK. cells did not
recycle as well as other activated T-cells and/or NK cells. Their work also suggested that
the effector cells could produce stasis of glioma by producing lymphokines such as tumor
necrosis factor, leukoregulin, interferon, and lymphotoxin (Merchant,
The results of this study by Kruse

R et aI., 1 986).

et aI., 1 989, showed that the production of ASL

was labor intensive, involving long-term culture and a greater chance of contamination.
Kruse

et ai., 1 989, studied the LAK. cells and ASL preparations and compared them to

the starting PBL by growth and viability measurements, cytotoxicity, phenotype
expression using specific monoclonal antibodies to characterize cell surface proteins, and
morphology as seen by electron microscopy. They determined that the two preparations
were distinct and that both were tumoricidal against known tumor cell lines. However,
LAK. cells and ASL derived from the peripheral blood of patients with intrinsic
tumors exhibited a wide variation in their capacity for

brain

in vitro growth. This could be

explained, in part, to the chemotherapy that patients received (Kruse et

ai., 1 989) . The
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modern vaccine story starts in the 1 940s and 1 950s with a fundamental discovery of
tumor immunology. Scientists found that when chemicals or viruses induced tumor in
mice, the tumor bore Ags that could immunize other mice of the same strain against
transplants of the tumor. Subsequent studies showed that immune system cells known as
T lymphocytes taken from immunized animals could transfer immunity against tumors in
healthy animals of the same strain. Workers also devised techniques to show that the T
cells from immunized mice could kill tumor cells grown in test tubes as well (Old, L.,
1 998). Antibodies elicited by the tumor cells generally failed to transfer immunity or kill
tumor cells.
The next challenge was to isolate the tumor Ags recognized in this system so that
they might be tested in a vaccine. Thierry Boon, 1 993, and his colleagues at the Ludwig
Institute for Cancer Research in Brussels developed a method to do just that (Old, L.,
1 998). The technique revealed two main categories of tumor Ags that evoked a T cell
response in melanoma patients. According to Old, L., 1 998, the first category of Ags
called MAGE, BAGE, and GAGE that were produced by tumor cells but not by normal
cells outside the testes. The second category of Ags, including tyrosinase and Melan A,
were called differentiation Ags; they were made from by both melanoma cells and
melanocytes, normal cells from which the tumor cell arises.
Another source of information about potential tumor Ags comes from the
d iscoveries concerning genetic changes in cancer cells. Among the most attractive targets
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for vaccines are abnormal proteins that are made when genetic mutations turn normal
genes into cancer-promoting versions. A long list of cancer-related genes - known as
oncogenes and tumor suppressor genes - are being compiled. Although much uncharted
areas lie ahead, there are now more vaccine-based therapies than before and promise
hope for the future.
The studies that comprised the formal research basis for this dissertation included
the following projects:

1 ) examination of the ability o f a 1 ° vaccination to protect against

RT-2 tumor and the demonstration of that specificity; 2) examination of the ability of a

1 0 and 20 vaccination paradigm to provide protection against an I C challenge of viable
RT-2 glioma cells; 3) examination of memory T cells in vaccinated and aged rats and 4)
examination of depletion studies to see if passive transfer of effector/memory cells was
possible.
To address the questions put forth, a highly immunogenic glioma cell line (RT-2)
was used. The RT-2 glioma cell line is uniformly lethal, whether implanted s.c. or IC. It
provides an efficient animal model in which to explore the efficacy of lymphokine and
cellular immunotherapy for brain tumors. The RT-2 glioma model has been used
extensively in our lab and others, is well characterized, and shares many features with
human gliomas.
We have described an experimental system in which vaccination with irradiated
RT-2 glioma cells activated an immunological response against the tumor. This was
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achieved in the 1 0 vaccination paradigm with 30% survival and in the 1 0 and 20
vaccination paradigm with 1 00% survival seen in animals with IC challenge in the right
cerebral hemisphere with viable RT-2 tumor cells. These data have described an
experimental system in which a population of resting, primed CD4+ T lymphocytes and
CD8+ CTLs can be generated in vivo and migrate to and initiate an immune response to
the tumor cells.
Immunological memory is described as the capacity of the immune system to
respond faster and more efficiently against an Ag it has encountered in the past. T cell
memory is believed to result from an increase in the frequency of Ag-specific T
lymphocytes (Ahmed, R. and Gray, D., 1 996; and McHeyzer-Williams, M. and Davis,
M., 1 995). Our results suggested that these populations of cells contributed to the 1 00%
survival rate.
Specialized cells known as memory T cell and B cells, and long-lived effector B
cells (plasma cells), which constitutively secrete high-affinity 'neutralizing' antibodies,
are the basis of immunologic memory (Kaech, S., et aL, 2002). The memory T cell
compartment consists of both CD4+ and CD8+ T cells that acquire effector functions to
kill infected cells andlor secrete infl ammatory cytokines that inhibit the replication of
pathogen. Effector CD4+ T cells also help B-cell responses and enhance CD8+ T cell
development, through the activation of APCs or secretion of cytokines, such as IL-2, IL-4
and IL- 1 5 . Although there might be interesting parallels between T - and B-cell
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development, this work focused primarily on the formation of effector and memory T
cells.
In the first study, we found that a 1 ° vaccination of irradiated RT-2 cells in the
HFPs or NN saw 30% survival of experimental animals. This was promising data that
directed the next set of experiments. Again, in the second study a vaccination paradigm
followed the first experiment. This one required a 1 ° and 2° vaccination of irradiated cells
in the NN and HFPs. Complete survival was attained in the experimental animals and all
control animals succumbed to tumor.

In the third set of experiments, we treated long-lived immunized rats with a
secondary IC challenge in the opposite hemisphere 1 80 days post first IC challenge. This
group of animals also resulted in 1 00% survival in the experimental rats and no survivors
for the control group.
The fourth experiment was performed to answer the questions if we could
passively transfer memory lymphocytes from spleen leukocytes from long-lived
immunized and challenged rats. This was done in the form of depletion studies. The
results were interesting in that the CD8+ T cell depleted group survived longer than the
CD4+ T cell depleted group. Future studies should look at the naIve and memory
populations using the CD45 mAbs markers that are available for humans, mice and rats.
Then one could look at the relative numbers of naIve T cells versus memory T cells
during a vaccination or vaccinations. The cytokines 1L-2 and 1L-4 involvement in CD4+

1 00

Th- l and Th-2 response versus CD8+ CTL response should be looked at more closely to
determine the roles of these two cytokines in memory cell production.
The role of CD4+ cytotoxic T cells should also be studied to see if they have a
potential role in prolonging survival in tumor-bearing rats or provide protection from
development of tumor. Vaccination has had an important role in reducing the mortality
and morbidity that is caused by infectious diseases. The ultimate goal of a vaccine is to
develop long-lived immunological protection, whereby the first encounter with a
pathogen is 'remembered' , which leads to enhanced memory responses that either
completely prevent reinfection or greatly reduce the severity of disease.
Many promising opportunities wait to be studied. and they give us reason to
expect that powerful immunologic therapies will one day become a reality.
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